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I Summary 
 
Cystic Fibrosis (CF) is the most common lethal monogenic autosomal recessive 
disease in the Caucasian population. It´s characterized by a quick loss of pulmonary 
function, with obstruction of the airways caused by the accumulation of mucus and the 
bacterial infections that follows.  
This disease is caused by various mutations on the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) gene in chromosome 7 which lead to a dysfunctional 
product. F508del (deletion of a phenylalanine in the 508º position of the protein) is the 
most predominant disease-causing mutation between the 1949 already known. 
CFTR is expressed in luminal membranes of both secretory and absorptive epithelia, 
where it not only works as a chloride channel but also controls a number of other ion 
channels and transporters, being crucial to the ionic flow on epithelia. Among these other 
channels is the Anoctamins family, better known as calcium (Ca2+) -activated Cl- 
channels (CaCCs). CaCCs mediate Ca2+-dependent Cl− secretion in glands and flat 
epithelia and modify cellular responses to adequate stimuli in muscle, nerve and 
receptors. 
Some studies already reported a functional relationship between these two entities, 
however the mechanism behind this crosstalk is still unknown.  
The aim of this work was to understand whether CFTR has a regulatory role on Ano1 
and Ano6 biogenesis and trafficking, beyond the apparent functional relationship and if 
this is impaired in CF patients. To achieve this we looked into Anoctamins’ expression, 
cell localization, function and direct interaction with CFTR in cells expressing WT-CFTR 
and in cells mimicking CF disease which expressed F508del-CFTR. This study was 
performed always having in mind that the disclosure of the relationship between these 
two protein families with similar function could shed a light on a new alternative target to 
fight against CF and somehow circumvent the complex process that is targeting CFTR, 
given the vast range of its mutations which cause an equally wide range of anomalies. 
The Anoctamin (Ano1, Ano6, Ano9 and Ano10) endogenous expression was 
quantified by semi-quantitative polymerase chain reaction (PCR) and compared in cystic 
fibrosis bronchial epithelial (CFBE) cells stably expressing either WT-CFTR or F508del-
CFTR. Then on baby hamster kidney (BHK) cells, cell localization of Ano1 and Ano6 was 
evaluated both in the presence of WT-CFTR and F508del-CFTR by microscopy. 
Physical interaction between CFTR and Ano1 or Ano6 was also assessed by 
performing a co-immunoprecipitation assay. 
Finally, Ano1 and Ano6 functions were studied in the presence of WT-CFTR and 
F508del-CFTR and evaluated by patch clamp. 
Overall the results showed that: 
- For both CFBE WT- and F508del-CFTR cells, Ano6 is the most expressed 
anoctamin between Ano1, 6, 9 and 10 and that this cell line does not express 
Ano10; 
- Ano1 and 6 are more expressed on CFBE WT-CFTR cells when compared to 
F508del-CFTR, and although not statistically significant Ano9 mRNA levels are 
much higher in WT-CFTR expressing cells than in F508del-CFTR cells; 
- Ano1 is mostly located on the cell membrane in both BHK WT-CFTR and F508del-
CFTR cells. However the expression level in significantly higher in WT than in 
F508del-CFTR cells; 
- Ano6 expression on the cell membrane is not so clear since that in the presence 
of both CFTR forms the protein was also detected intracellular; 
- Both Ano1 and Ano6 have a direct interaction with CFTR, although this is not true 
for F508del-CFTR; 
- The interaction between CFTR and Ano1 does not appear to be made through 
PDZ scaffold proteins; 
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- Ano1 is constitutively active on both BHK cell lines stably expressing WT- and 
F508del-CFTR when transiently transfected with Ano1; 
- Ano1 seems to inhibit WT-CFTR channel activation; 
- The mutation into Ano1’s PDZ binding domain does not seem to affect WT-CFTR 
currents by Ano1, corroborating the non-interaction through the PDZ binding 
domain. 
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II Resumo 
 
A Fibrose Quística (FQ) é a doença autossómica recessiva letal mais comum na 
população caucasiana com uma prevalência de 1 em 2500-4000 nascimentos. 
Apresenta como sintomas característicos um declínio rápido na função pulmonar, com 
obstrução das vias aéreas devido à ineficaz remoção de muco e consequentes infeções 
bacterianas recorrentes. Estas alterações estão associadas a um ambiente de 
hiperinflamação, que exacerba os processos de remodelação do tecido pulmonar e 
acaba por culminar na fibrose dos tecidos e perda da sua função. Além deste fenótipo 
respiratório, os pacientes apresentam ainda insuficiência pancreática, obstrução 
intestinal e hepática, e elevados níveis de infertilidade masculina. 
Esta doença tem como causa mutações ocorridas num gene, localizado no 
cromossoma 7 (7q31), que codifica para uma glicoproteína com 1480 resíduos de 
aminoácidos, designada Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR). Esta proteína tem a função de canal de cloreto (Cl-) presente na membrana 
apical de células epiteliais, regulando o transporte transepitelial de iões e água, quando 
ativada por fosforilação via proteína cinase A (PKA) dependente do cAMP. Sendo que 
a disrupção da função da CFTR leva a um desequilíbrio iónico do líquido que reveste as 
vias respiratórias, airway surface liquid (ASL), levando ao aumento de espessura e 
viscosidade do muco provocados pela sua desidratação.  
A deleção de um único aminoácido, uma fenilalanina na posição 508 (F508del) está 
presente em aproximadamente 90% dos pacientes com FQ, sendo a mais comum de 
entre as mais de 1949 conhecidas. Esta mutação afeta o correto processamento da 
proteína que, devido a um folding incorreto, fica retida intracelularmente a nível do 
retículo endoplasmático (RE) onde é rapidamente enviada para a via de degradação 
proteolítica do proteassoma associada ao RE, não chegando assim à membrana 
plasmática. 
A função fisiológica da CFTR no epitélio vai para além do seu papel como canal de 
Cl-, existindo várias evidências da sua atuação como proteína reguladora de outros 
canais iónicos relevantes na patofisiologia da FQ. Entre eles encontram-se o canal de 
sódio epitelial (ENaC) e canais de potássio como KVLQT-1. Outros canais que 
possivelmente interatuam com a CFTR são os canais de cloreto ativados por cálcio 
(CaCC) e outwardly rectifying (ORCC). Os primeiros têm a função de transporte iónico 
transepitelial em células secretoras e são caracterizados por apresentarem uma 
ativação dependente da subida dos níveis de Ca2+ intracelular. 
Por sua vez, os ORCC distinguem-se por demonstrarem uma relação I/V outwardly 
rectifying e serem ativados por despolarização celular e via PKA e UTP extracelular. 
A produção de corrente pelos CaCCs encontra-se aumentada nas vias respiratórias 
de doentes com fibrose quística, provavelmente para tentar compensar de algum modo 
a ineficácia da CFTR. Enquanto que a ativação dos ORCC pela PKA encontra-se 
afetada nos tecidos de doentes com fibrose quística. 
A relação da CFTR com estes canais tornou-se ainda mais interessante quando, em 
2008, estes foram molecularmente identificados como Anoctaminas, uma família de dez 
proteínas que apresenta semelhança estrutural, com oito segmentos transmembranares 
e um poro entre os segmentos 5 e 6, mas diferenças em termos funcionais. A 
Anoctamina 1 é reconhecida como o grande componente dos CaCCs, enquanto que a 
Anoctamina 6 atua como ORCC. 
O trabalho elaborado teve como objetivo explorar esta relação entre a CFTR e as 
Anoctaminas (mais especificamente Ano1 e Ano6). Foi estudado o tipo de interação 
existente entre ambas as proteínas (física ou só funcional) e o impacto que a presença 
da CFTR-WT ou CFTR-F508del teria na expressão, localização celular e função da 
Ano1 e Ano6. Nunca esquecendo o grande potencial desta nova família de proteínas 
como alvo farmacológico alternativo para a terapêutica da fibrose quística. 
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Inicialmente estudou-se a expressão endógena das anoctaminas (Ano1, 6, 9 e 10) 
nas células CFBE, estavelmente transfectadas com CFTR-WT ou F508del, através da 
técnica de PCR semi-quantitativo. De seguida, em células BHK, foi estudada a potencial 
influência da CFTR-WT e F508del na localização celular da Ano1 e 6, usando técnicas 
de microscopia. 
Foram também realizados ensaios de co-imunoprecipitação com o objetivo de 
compreender se a interação entre a CFTR e a Ano1 ou 6 seria física/direta e não só 
funcional. 
Finalmente, investigou-se o impacto da CFTR-WT e F508del na funcionalidade das 
anoctaminas Ano1 e 6 através de técnicas de patch clamp. 
Os resultados obtidos sugerem que: 
- Em células CFBE, a Ano6 é a Anoctamina mais expressa de entre a Ano1, 6, 9 
e 10 e que estas células não apresentam expressão endógena de Ano10; 
- A Ano1 e 6 são significativamente mais expressas em células CFBE 
expressando estavelmente CFTR-WT, os níveis de mRNA da Ano9 são bastante mais 
elevados nas células que expressam a forma WT, mas não estatisticamente diferentes 
dos níveis detetados nas CFBE CFTR-F508del; 
- Tanto em BHK CFTR-WT como em CFTR-F508del, a Ano1 localiza-se 
maioritariamente na membrana plasmática. Contudo, os níveis de expressão 
membranar são significativamente maiores nas células que expressam CFTR-WT; 
- A Ano6 encontra-se não só localizada na membrana plasmática como também 
intracelularmente; 
- Tanto a Ano1 como a Ano6 apresentam uma interação direta com a CFTR-WT. 
No entanto, tal não acontece quando a CFTR-F508del é expressa; 
- A interação entre a CFTR e a Ano1 não se efetua através de proteínas de 
ancoragem ao domínio PDZ; 
- A Ano1 encontra-se constitutivamente ativa quando transientemente expressa 
em células BHK que expressam estavelmente CFTR-WT ou F508del; 
-  A Ano1 parece inibir a ativação das correntes produzidas pela CFTR-WT; 
-  As experiências funcionais corroboram a ausência de interação direta entre Ano1 
e CFTR através do domínio de ligação PDZ. 
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III Abbreviations 
 
A549 – human alveolar epithelial cells (cell line) 
ABC- ATP-binding cassete 
AC1 – adenylyl cyclase I 
ASL – airway surface liquid 
ATP – adenosine triphosphate 
BHK – baby hamster kidney (cell line) 
BSA – bovine serum albumin 
C – cysteine 
CaCC – calcium-activated chloride channel 
CAM – calcium-modulated protein 
CAMK – Ca2+/calmodulin-dependent kinase 
cAMP – cyclic adenosine monophosphate 
CAP70 – CFTR associated protein of 70 kDa 
Cch – carbachol 
cDNA – complementary DNA 
CF – cystic fibrosis 
CFBE41o- / CFBE – cystic fibrosis bronchial epithelial (cell line) 
CFP – cyan fluorescent protein 
CFTR – cystic fibrosis transmembrane conductance regulator 
CLC – chloride channel 
CPAE – calf pulmonary artery endothelial cells 
dNTP – deoxynucleoside triphosphate 
DAPI – 4',6-diamidino-2-phenylindole 
EDTA – ethylenediaminetetraacetic acid 
ENaC – epithelial sodium channel 
ER – endoplasmic reticulum 
ERAD – endoplasmic-reticulum-associated protein degradation 
Erk1, 2 – extracellular signal-regulated protein kinase 1 and 2 
ERM – ezrin–radixin–moesin protein family 
ERQC – endoplasmic reticulum quality control 
FBS – fetal bovine serum 
FSK / F – forskolin 
GABA – gamma-aminobutyric acid 
GFP – green fluorescent protein 
eGFP – enhanced green fluorescent protein 
GPCR – G protein-coupled receptors 
HEK – human embryonic kidney (cell line) 
HeLa – human cervical carcinoma (Henrietta Lacks) (cell line) 
HRP - horseradish peroxidase 
Hsp40/70/90 – heat shock 40 kDa / 70 kDa / 90 kDa protein 
IBMX – 3-isobutyl-1-methylxanthine 
IP – immunoprecipitation 
IP3 – inositol triphosphate 
IRBIT – IP3 receptor-binding protein 
IRES – internal ribosome entry site 
K – lysine 
KD – equilibrium dissociation constant 
MSD – membrane-spanning domain 
NBD – nucleotide binding domain 
NFM – non fat milk 
NHERF1 – Na+/H+ Exchanger Regulatory Factor 
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NKCC1 – Na+/2Cl−/K+ co-transporter 
ORCC – outwardly rectifying chloride channel 
P – phosphorylation site 
PBS – phosphate buffer saline 
PBS-T - phosphate buffer saline with tween 
PCR – polymerase chain reaction 
PDZ – post synaptic density protein (PSD95), Drosophila disc large tumor suppressor 
(Dlg1), and zonula occludens-1 protein (zo-1) 
PKA – protein kinase A 
PLC – phospholipase C 
PM – plasma membrane 
PP2A – protein phosphatase 2 
PPase – protein phosphatase 
PS – phosphatidylserine 
PYK2 – proline-rich tyrosine kinase 2 
R – arginine 
RD – regulatory domain 
RNC – ribosome-nascent chain complex 
SRP – signal recognition particle 
TBS – tris buffer saline 
TBS-T – tris buffer saline with tween 
TM – transmembrane segments 
UTP – uridine triphosphate 
Vm – membrane voltage 
YFP – yellow fluorescent protein 
eYFP – enhanced yellow fluorescent protein 
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1 Introduction 
 
1.1 Cystic Fibrosis – Historical overview 
 
Cystic Fibrosis (CF) is the most common lethal autosomic recessive disorder in the 
Caucasian population. It affects 1 in 2500 to 6000 live births and has a carrier frequency 
of 1 in 25 to 40 individuals. The disease frequency is variable among different ethnic 
groups, being the highest in Northeastern Europe and quite rare among Oriental 
populations (1:90,000)[1]. 
It was first described in 1938 by Anderson and colleagues (who came to find that CF 
has a recessive autosomal pattern inheritance) as a digestive disorder, since the first 
detectable symptoms were intestinal obstruction in newborns and malnutrition in infants, 
being associated with a progressive fibrosis of the pancreatic tissue. Because infants 
died at a very young age, these were the only symptoms that were noticeable. However 
the healthcare developing allowed to overcome this situation and then problems in the 
respiratory tract became the major cause for morbidity and mortality. 
The 1950s saw the beginning of the sweat test, the standard test now used for 
diagnosing cystic fibrosis. An excess of salt in the sweat of patients was identified, which 
was later attributed to a defect in chloride transport in the sweat glands. This defective 
chloride transport was also detected in the lung, pancreas and intestinal epithelium, the 
most affected tissues[1]. 
In 1989, the gene responsible for the disease was identified and named Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR). This gene encodes for a 
cAMP-regulated chloride channel expressed in a number of epithelial tissues. It was 
found to harbour mutations in all CF patients analysed, the most common of which being 
a deletion of three nucleotides encoding for a phenylalanine in 508º position in the protein 
(F508del or ΔF)[2]. This mutation is present in about 70% - 90% of all patients, and 
represents only one of the 1949 mutations in the CF gene described until now[3]. 
Availability of the gene sequence and direct mutation analysis were turning points in 
the history of CF and opened a new chapter of molecular and cellular studies in CF 
research. 
The study made through the years on this complex disease allowed the average life 
expectancy of the patients to reach the 37 years, compared to a mere five years around 
50 years ago and only now therapies related with the molecular basis of the disease, 
resulting from an intensive study on the biogenesis and function of CFTR, are reaching 
the patients. 
 
 
1.2 Cystic Fibrosis – The Phenotype 
 
Cystic fibrosis in its classic and most common form manifests with chronic obstructive 
lung disease, exocrine pancreatic insufficiency, elevated sweat chloride concentration 
and in males infertility due to obstructive azoospermia[4]. 
The respiratory tract has the biggest involvement on the clinical features of this 
disease. The reduced volume of ASL and development of a thick, dehydrated airway 
mucus cause the failure of mucociliary clearance, the lungs’ innate defence mechanism. 
The mucociliary dysfunction leads to an ineffective clearance of inhaled bacteria 
meaning recurring infections[5]. The patients’ lungs develop chronic hyperinflammation 
from a very early age, exacerbating tissue remodelling processes and fibrosis. 
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The end result of the abnormalities described above is irreversible airway damage 
with bronchiectasis and respiratory failure in most patients, being the main cause of 
morbidity and mortality among CF patients. 
The involvement of the gastrointestinal tract is also common, with 85% of the patients 
presenting pancreatic insufficiency as a result of the obstruction of the pancreatic ducts. 
Around 10% of newborns with CF present a form of intestinal obstruction called 
meconium ileus, and 2 to 5% develop liver complications at some time during the course 
of the disease[6]. 
Elevated concentrations of sodium chloride in the sweat is characteristic of CF 
patients; in fact, this is the basis for the already referred most common diagnostic test 
for cystic fibrosis where the sweat electrolyte levels are measured[5]. 
Finally, in adults with CF, infertility is almost universal in males, due to congenital 
bilateral absence of the vas deferens. 
Most of the different therapeutic approaches that have been used in the last 25 years 
focus mainly on the amelioration of these symptoms. This  includes antiinflammatory and 
antibiotic drugs, as well as treatments directed towards restoring the levels of airway 
surface liquid, preventing mucus accumulation and overcoming the nutritional defects in 
patients[7]. 
 
 
1.3 Cystic Fibrosis – CFTR mutations 
 
The CFTR gene (or ABCC7) is located on the long arm of chromosome 7 (7q.31.2) 
and is one of the longest in the human genome. Consists of a TATA-less promoter and 
27 exons spanning about 215 kb of genomic sequence[4]. It can suffer several disease 
causing mutations that can be grouped in 6 different classes, according to the functional 
defect conferred by them. Class I mutations abolish protein production. Class II 
mutations result in defective protein processing; this is the case of the most common 
F508del mutation. Class III proteins confer defects in the regulation of the channel. Class 
IV mutations have a defective ion conductance. Class V mutations result in decreased 
protein synthesis. Class VI mutations decrease the protein’s stability at the cell surface. 
Currently, therapeutic focused research includes a multiplicity of approaches: search 
of candidate modifier proteins to identify new potential therapeutic targets and 
pharmacological therapy to rescue the molecular defects responsible for CF are the most 
important topics under development[7]. 
Kalydeco, previously named VX-770, is the first drug developed and approved by the 
Food and Drugs Administration in the USA that is centred on the molecular basis of CF. 
VX-770 is a CFTR Potentiator (corrects the gating defect on CFTR) approved for patients 
with the G551D mutation of cystic fibrosis, which accounts for 4-5% of CF cases. 
There are ongoing clinical trials for new drugs combining VX-770 with other 
compounds (VX-809 and VX-661), that correct the trafficking defect of proteins with other 
mutations, like F508del[8]. 
 
 
1.4 CFTR – Structure and function 
 
The CFTR gene encodes a protein (1480 aminoacid residues) with a symmetrical, 
multi-domain structure. The proposed domain structure was based on a comparison of 
CFTR with members of the ATP-binding cassette (ABC) transporter family, being 
composed of two motifs, each containing a membrane-spanning domain (MSD) that is 
usually but not always composed of six transmembrane segments (TMs) and a 
nucleotide-binding domain (NBD) that contains sequences predicted to interact with ATP 
and harbours the F508del mutation. In CFTR, the two MSD-NBD motifs are linked by a 
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unique domain, called the regulatory domain (RD), that contains multiple consensus 
phosphorylation sites (P) many charged amino acids[9] (Figure 1.1). CFTR C-terminus is 
also a highly regulatory site that binds protein kinases together with at least one 
phosphatase[10]. This region is known as well to accommodate a PSD95, Dlg1, ZO-1 
(PDZ)-binding motif through which it is involved in a complex PDZ-based protein 
interaction networks with a number of proteins. These multivalent PDZ proteins (for 
example CAP70 and NHERF1) have been proposed to regulate the gating of CFTR 
channels at the plasma membrane (PM), being able to enhance CFTR channel activity 
in excised inside–out membrane patches[11]. 
 
CFTR is expressed in 
luminal membranes of both 
secretory and absorptive 
epithelia, where it works as 
a chloride channel[13]. 
Contrary to other ABC 
transporters, CFTR is 
incapable of actively driving 
ion transport against a 
gradient; instead, it 
functions as a passive 
channel that allows 
bidirectional flow of ions 
when open[10]. Channels 
like CFTR exhibit several 
distinguish characteristics: 
1) small single-channel 
conductance (6-10 pS); 2) 
linear current-voltage (I-V) 
relationship; 3) selectivity for 
anions over cations; 4) show 
time-voltage independent gating behaviour; 5) regulated by cAMP-dependent 
phosphorylation and by intracellular nucleotides. In CFTR the MSDs, the NBDs and RDs 
are responsible for these features. 
The MSDs contribute to the formation of the Cl—selective pore, the NBDs hydrolyze 
ATP to regulate channel gating and RD phosphorylation controls channel activity[9]. 
CFTR channel is tightly controlled by the balance of kinase and phosphatase activity 
within the cell and by cellular ATP levels.  
Activation of the cAMP-dependent protein kinase (PKA) causes the phosphorylation 
of multiple serine residues within the RD. Once the RD is phosphorylated, channel gating 
is regulated by a cycle of ATP hydrolysis at NBDs (Figure 1.1 B). Finally, protein 
phosphatases (PPases) dephosphorylate the RD and return the channel to its quiescent 
state[9] (Figure 1.1 A). 
The raising of intracellular cAMP is achieved in membrane-confined regions, most 
likely through CFTR recruitment of its own regulatory machinery to its proximity, 
comprising receptors, adenylate cyclases, phosphodiesterases and kinases (in 
experimental preparations, increased cAMP is attained through global stimulation of the 
adenylate cyclase by forskolin (FSK or F), which floods the entire cytosol with cAMP and 
it is not compartmentalized). The formation of multiple-protein macromolecular 
complexes in subcellular microdomains increases the specificity and efficiency of 
signalling towards CFTR and the membrane-local cAMP concentrations can further be 
controlled by cell excretion. The previously mentioned C-terminal region of CFTR is 
essential for this process interacting with proteins carrying ERM (ezrin, radixin, moesin) 
domains that link the CFTR complex to the cortical actin network enabling then an 
extensive network of protein interactions[10]. 
Figure 1.1 – Model of CFTR topology and Cl- channel regulation. 
This schematic model shows the regulation of CFTR from an 
inactive (A) to an active (B) state, through cAMP-dependent 
phosphorylation at the RD and ATP binding and hydrolysis at the 
NBDs. Retrieved from Amaral (2013)[12]. 
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Besides this function as a Cl- channel CFTR can also act as a Cl-/HCO3- exchanger. 
It was observed that after stimulation of colonic human cells with FSK the Cl-/HCO3- 
exchange activity was increased and that was independent of CFTR Cl- channel 
activity[14]. 
CFTR is also involved in glutathione transport. Through macroscopic current 
recordings from excised membrane patches, was observed that glutathione is permeant 
in the CFTR channel. This permeability may account for the high concentrations of 
glutathione that have been measured in the ASL. Furthermore, loss of this pathway for 
glutathione transport may contribute to its reduced levels observed in the airway surface 
fluid of cystic fibrosis patients, which has been suggested to contribute to the oxidative 
stress observed in the lung in this disease[15]. 
CFTR not only generates a Cl- conductance but also controls a number of other ion 
channels. These include the calcium-activated chloride channel (CaCC) and the 
outwardly rectifying chloride channel (ORCC). It has been reported that CFTR inhibits 
endogenous Ca2+ activated Cl- currents in Xenopus oocytes, bovine pulmonary artery 
endothelium and isolated parotid acinar cells[16–18]. CaCC was also found to be 
augmented in airways of patients suffering from cystic fibrosis[19].  
The ORCC regulation by PKA was found to be defective in CF airway epithelia when 
compared with that of normal epithelia and, once complemented with the WT-CFTR 
gene, PKA regulation of ORCCs was corrected[20, 21]. In 2008, the long search for the 
Ca2+ activated Cl- channel, succeeded in the identification of the Anoctamin protein family 
as CaCC[10, 22, 23]. These proteins may represent a family of Ca2+-activated Cl- channels 
with different affinities for Ca2+. Kunzelmann and colleagues found that the Ca2+-
activated Cl- channel function of anoctamin 1 (Ano1; TMEM16A) was inhibited during 
activation of CFTR, while CFTR currents were attenuated by overexpression of 
Anoctamin 1[16]. 
Also to ORCC an association with the anoctamin family was found. Recently the main 
component of these ORCCs was identified as Anoctamin 6 (Ano6; TMEM16F)[24]. It is 
now established that expression and activation of CFTR induces a typical CFTR Cl− 
conductance and in parallel activates outwardly rectifying Cl− currents[24, 25]. 
This subject will be followed with more detail on section 1.6. 
It is also known the interaction between CFTR and other proteins like the epithelial 
sodium channel (ENaC) and KVLQT-1 K+ channels. 
Na+ conductance was found enhanced in apical membranes of lung epithelia and 
intestinal mucosa of CF patients and an inhibition of ENaC by CFTR was also detected 
in rat colonic epithelial cells and in normal human but not in CF airways[25]. 
The K+ conductance was discovered to be enhanced when CFTR was expressed in 
Xenopus oocytes and activated by intracellular cAMP[25]. 
 
 
1.5 CFTR – Folding and trafficking 
 
CFTR folding and intracellular trafficking are highly regulated processes that once 
disrupted lead to abnormalities of water, chloride, and/or bicarbonate transport which 
results in the already referred dysfunction of target tissues including: pancreatic 
insufficiency, increased sweat chloride, intestinal obstruction, and most importantly, 
chronic pulmonary infection, inflammation, and ultimately death due to respiratory 
failure[26, 27]. 
In CFTR biogenesis only 20%-40% of newly synthesized nascent chains acquire the 
native conformation, exit the endoplasmic reticulum (ER), and undergo complex 
glycosylation in the Golgi compartment[28]. Biogenesis occurs at the ER, and requires 
coordinated folding of individual domains in three distinct cellular compartments: the ER 
membrane, the ER lumen, and the cytosol. This compartmentalization takes place as the 
nascent chain emerges from the ribosome[26]. NBD1 domain folds largely co-
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translationally, but the native structure of NBD2 and, hence, of the full channel are 
attained post-translationally[28].  
CFTR, as membrane protein, is firstly targeted to the surface of the ER during 
synthesis by the cytosolic signal recognition particle (SRP), bringing the ribosome 
nascent chain complex (RNC) to the Sec61 translocon complex, which co-translationally 
inserts the protein in the ER membrane[26]. The folding process is then facilitated by a 
large cohort of cytosolic and luminal chaperones including Hsp70, Hsp40, Hsp90, 
calnexin, calreticulin and others[29]. Cytosolic chaperone interactions begin co-
translationally during synthesis as Hsp/c70 binds and presumably shields extended 
hydrophobic regions of the nascent chain to prevent aggregation. Whereas the luminal 
chaperones calnexin and calreticulin promote the ER retention of core glycosylated 
CFTR folding intermediates until their folding cycle or degradation is completed[28]. 
During the maturation process, CFTR goes through several steps of glycosylation, first 
in the ER and then in the Golgi apparatus. In the ER, a branched 14-unit oligosaccharide 
is added at asparagine residues 894 and 900 in the fourth extracellular loop in a process 
called N-glycosylation or core-glycosylation[30], which stabilizes the CFTR folding 
directly[28]. This high-mannose oligosaccharide core is then processed by glucosidases 
and the resulting monoglucosylated intermediate can be recognised by luminal 
chaperones that prevent unwanted interactions and aggregation with other molecules. 
The protein then dissociates from calnexin/calreticulin and has its last glucose residue 
removed. 
Less than 30% of newly synthesized immature CFTR molecules ever acquire complex 
oligosaccharides indicative of maturation to post-ER compartments, which indicates a 
relatively high inefficiency in this process[31]. 
If the folding is incorrect the chaperone–CFTR interaction triggers the ubiquitination-
dependent endoplasmic-reticulum-associated protein degradation (ERAD). Distinct E3 
Ub ligases are responsible for the co- and post-translational ubiquitination of non-native 
CFTRs that recognize misfolding of the N- and C-terminal CFTR regions[28]. 
Most of the CFTR bearing the F508del mutation is degraded before evading the ER 
into the Golgi by the endoplasmic reticulum quality control (ERQC) system[32]. 
On the other hand, if the folding is successful CFTR is released from the ER, loaded 
into COP II-coated vesicles that traffic to the Golgi, where the major glycan processing 
occurs. Other nonconventional trafficking pathways have also been described for 
CFTR[33]. 
In the Golgi complex, CFTR is processed by multiple Golgi glycosyltransferases, 
creating the fully mature form of CFTR that is incorporated into secretory vesicles and 
delivered to the apical membrane where these bulky glycans are exposed to the 
extracellular space.  
While at the PM, CFTR can be recycled from early endosomes back to the PM, via 
Rab11/ Myo5b-driven recycling endosomes[34], or driven away from the recycling 
pathway into late endosomes, by Rab7, followed by degradation[35]. 
The CFTR internalization into the PM is a rapid process compared with CFTR 
biosynthesis and maturation, which suggests that is this last step of recycling of 
internalized channels the key process in maintaining a functional pool of CFTR at the 
PM[33]. 
 
 
1.6 CFTR and Anoctamins 
 
1.6.1 Crosstalk between cAMP and Ca2+ signalling 
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CFTR is not only a regulator of multiple transport proteins controlled by numerous 
kinases but also participates in many signalling pathways that are disrupted in CF[10]. 
cAMP activation pathway and Ca2+ signalling were, for a long time, considered 
independent entities. However, lately crosstalk between cAMP (involved in CFTR 
activation) and Ca2+ dependent secretion has been suggested and may occur at different 
levels. There is evidence for at least five Ca2+-dependent mechanisms of CFTR 
activation: 1) through P2Y2 receptors (G-protein coupled purinergic nucleotide 
receptors) and phospholipase C (PLC), 2) upregulation of adenylyl cyclase by Ca2+ 
leading to conventional PKA-mediated phosphorylation of CFTR, 3) stimulation of 
PYK2/Src, which inhibits protein phosphatase 2 (PP2A) and thus increases serine 
phosphorylation on CFTR, 4) direct tyrosine phosphorylation of CFTR by the PYK2/Src 
complex, and 5) interaction with inositol triphosphate (IP3) receptor-binding protein 
(IRBIT) released with IP3. 
Kunzelman and coworkers showed that stimulation of P2Y2 receptors leads to 
activation of CFTR Cl- currents but once PLC (or calmodulin-dependent kinase (CAMK)) 
is inhibited, both CaCC and CFTR activation are completely abolished[36]. 
There is also evidence for CFTR activation through calcium-stimulated adenylyl 
cyclases. Verkman and colleagues showed that most chloride current elicited by Ca2+ 
agonists in primary cultures of human bronchial epithelial cells is mediated by CFTR 
through a mechanism involving Ca2+ activation of adenylyl cyclase I (AC1) and 
cAMP/PKA signalling[37]. 
Some other data supporting the cAMP/Ca2+ crosstalk suggest the involvement of 
tyrosine kinases in CFTR activation. In cells expressing the M3 muscarinic acetylcholine 
receptor (known to mobilize Ca2+ when activated), the agonist carbachol (Cch) caused 
strong activation of CFTR through two pathways; the canonical PKA-dependent 
mechanism and a second mechanism that involves tyrosine phosphorylation by Src[38]. 
The Proline-rich tyrosine kinase 2 (PYK2) is another tyrosine kinase involved in this 
activation process. It was found that the inhibition of PYK2 notably reduced the ability of 
spiperone to increase intracellular Ca2+ and Cl- secretion, playing a crucial role in the 
activation of CaCC and CFTR[39].  
This tyrosine kinase pathway can still influence CFTR activation through the activity 
of a protein phosphatase. PP2A, known to cause CFTR dephosphorylation, is strongly 
inhibited when phosphorylated by Src. Therefore, Ca2+-dependent activation of Src can 
enhance channel activity by inhibiting the dephosphorylation of PKA sites on CFTR[40]. 
cAMP can also enhance Ca2+ release from intracellular stores by stimulating PKA 
phosphorylation of the IP3 receptor. The IP3 receptor normally interacts with a protein 
called IRBIT, which inhibits IP3 receptor channel function and it is released when the 
receptor binds IP3. After dissociation from the endoplasmic reticulum, IRBIT can interact 
and regulate the activity of several transporters at the PM, including the sodium 
bicarbonate co-transporter and CFTR[41, 42]. 
The ultimate crosstalk between cAMP and Ca2+ is the one during transepithelial 
transport, where a potential relationship between CFTR and CaCCs is suggested. 
Notably enhanced Ca2+ activated Cl− currents have been detected in the airways of 
CFTR-knockout mice, in numerous studies with primary or permanent human airway 
epithelial cell lines and in native CF tissues[10, 43]. On the other hand, some results show 
that CFTR has an inhibitory effect on CaCCs[44]. Nonetheless, an interaction between 
these two entities is suggested. 
 
1.6.2 Calcium-activated Chloride Channels 
 
CaCCs are widely expressed and can be found in neurons; various epithelial cells; 
olfactory and photo-receptors; cardiac, smooth, and skeletal muscles; Sertoli cells; mast 
cells; neutrophils; lymphocytes; uterine muscle; brown fat adipocytes; hepatocytes; 
insulin-secreting beta cells; mammary glands; sweat glands; and Vicia faba guard cells. 
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They are involved in several physiologic processes as membrane excitability in cardiac 
muscle and neurons[45, 46], olfactory transduction[46], regulation of vascular tone[47], 
modulation of photoreceptor light responses[48] and, most importantly for this thesis, in 
epithelial secretion[19, 49–51]. 
The primary function of Cl− channels in secretory cells is transepithelial ion transport. 
Three factors dictate the direction of Cl− movement through CaCCs: the membrane 
potential, the Cl− concentration gradient and the concentration of intracellular calcium in 
the 0.2–1.0 µM range[48]. Firstly, Cl− is taken up by the basolateral Na+/2Cl−/K+ co-
transporter NKCC1. Na+ is pumped out by the basolateral Na+/K+-ATPase and 
basolateral K+ channels recycle K+ to the basolateral side leading to hyperpolarization of 
the membrane voltage (Vm) and supplying the necessary driving force for luminal Cl− 
exit. The activation of CaCC by intracellular Ca2+ signals is elicited through ATP 
stimulation of luminal Gq-coupled P2Y purinergic receptors inducing the increase of IP3 
production, or through basolateral hormonal stimulation[43] (Figure 1.2). 
When compared with cAMP/CFTR dependent Cl− secretion, Ca2+/CaCC-dependent 
secretion is much less sustained, due to the transient nature of the intracellular Ca2+ 
signal. 
These channels are also characterized to 
have the halide selectivity of SCN- > NO3- > 
I- >Br- > Cl- > F-, whereas the high 
permeable ions influence the channel 
activation accelerating it and slowing down 
deactivation[48]. 
It is believed that CaCCs act as an acute 
regulator of the airway liquid layer. Their 
contribution to the liquid layer homeostasis 
in murine airway epithelium probably 
explains the lack of a lung phenotype in 
mouse models of cystic fibrosis[52]. 
Given that both CFTR and CaCCs are 
apical Cl− channels and a functional 
interaction seems to be present, it has been 
proposed that the activation of CaCCs could 
serve as a bypass therapy for cystic fibrosis, 
but until recently this line has been hampered by the lack of specific activators of CaCCs 
and by the uncertainty about the molecular identity of these channels. In 2008, the search 
for the identity of these CaCCs came to a conclusion with the identification of anoctamin 
1 (Ano1; TMEM16A) and anoctamin 2 (Ano2; TMEM16B)[22, 23, 53]. 
 
 
1.6.3 Anoctamins 
 
Anoctamins are a family of ten different proteins, Anoctamin 1-10 (Ano1-10; 
TMEM16A-K), being Anoctamin 1 the one studied in more detail.  
Anoctamins tissue expression has a big overlay with CaCCs. They can be found in 
sensory receptors, different types of smooth muscles, heart, endothelium, neuronal 
tissues, and epithelial organs[54]. 
Anoctamins have eight putative TMs with both NH2 and COOH termini protruding into 
the intracellular medium. Based on mutagenesis experiments that resulted in altered ion 
selectivity, it has been proposed that TM5-TM6 flank a re-entrant loop thought to form 
the pore. It is because of these eight transmembrane segments structure and the anion 
selectivity that these proteins have been called Anoctamins[55, 56]. Specifically for Ano1 it 
is suggested the presence of several cysteine (C) and charged amino acids (like arginine 
(R) and lysine (K)) on the pore loop region, at least one glycosylation site at the last 
Figure 1.2 - Model for cAMP and Ca2+ 
dependent Cl− secretion in airways. Retrieved 
from Kunzelmann (2012)[43] 
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extracellular loop, the existence of non-canonical calcium-modulated protein (CAM) 
binding sites in the N-terminus and two putative extracellular signal-regulated protein 
kinase 1 and 2 (Erk1, 2) phosphorylation sites in the C-terminus (Figure 1.3). 
This protein family is also known to 
be a target for cell alternative splicing. 
For Ano1 this process involves the 
skipping/inclusion of at least three 
alternative segments, called b, c, and 
d, corresponding to exons 6b, 13, and 
15 and the possibility of a fourth 
region (segment a), located on the 
NH2 terminus, to be skipped when an 
alternative promoter is used (Figure 
1.3)[54, 55]. Four splicing isoforms of 
the olfactory Ca2+-activated Cl-
channel Ano2 were detected, with 
two alternative starting exons and 
alternative splicing of exon 4[57]. On 
intracellular membranes in muscle, 
Ano5 suffers an extensive alternative splicing generating 14 different isoforms[58]. For 
Ano6 four isoforms are known[59] and two for Ano7[60]. 
Even if the sequence homology within the putative pore region is considerable, 
Anoctamins overall homology is only moderate[54]. Mammalian subfamilies 1 and 2 are 
closely related, with about 60% amino acid identity, as are 3 and 4, and 8 and 10[58], 
although these only demonstrate an identity around 30% or below (Figure 1.4). The Ano 
family is now the second largest of the five known Cl− channel families (CLC, CFTR, 
ligand-gated GABA and glycine receptors[61], bestrophins[62] and anoctamins), being 
ligand-gated GABA and glycine receptors the largest. 
 
Figure 1.3 - Model for Ano 1 topology. Retrieved from 
Kunzelmann (2011)[54] 
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Figure 1.4 – Phylogeny of the Anoctamin family. Retrieved from Hartzell 2009[58] 
 
This molecular heterogeneity can be seen in the phenotypic diversity of CaCC 
currents. There appear to be at least four different types of CaCCs in different cell types 
and the channels may have multiple conductance states. Within the low conductance (1-
3 pS) CaCCs class, the channels can exhibit either linear or outwardly rectifying I-V 
curves, equilibrium dissociation constant (KD) values for Ca2+ over a 500-fold range, 
variable voltage sensitivity, and different susceptibility to rundown after excision of the 
patch. Rundown after patch excision has been interpreted to suggest that the channels 
are regulated by a factor which is lost upon excision[48]. 
CaCCs channels with higher conductances (8 pS) can exhibit linear I–V relationships 
(the case of Ano1 in HEK cells[22]). 
The highest conductance channels (40–50 pS), seen in airway epithelial cells[63] 
among other tissues, are outwardly rectifying. Whether these variances are explained by 
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different Ano members or different heteromeric combinations of Anos remains to be 
seen. 
Until now, Cl− channel activity has been clearly identified for Ano 1 and Ano 2[23, 64] 
and some Ca2+-activated Cl− currents generated by Ano 6 and Ano 7 were found, while 
Ano 5, 8, 9, and 10 did not produce any measureable currents[65], and Ano 7, -8, -9 and 
-10 were even detected mostly intracellular and not on the cell surface[66]. Ano1 was 
actually identified as the essential component for Ca2+-dependent Cl-secretion in several 
epithelial tissues and mucociliary clearance of mouse airways by studies of Cl- transport 
in Ano1 null mice[67]. 
On the other hand, Ano6 showed to induce Ca2+-dependent translocalization of 
phosphatidylserine (PS) from the inner leaflet of the PM to the outer leaflet (scramblase 
activity) and is therefore essential for platelet aggregation[68]. Ano6 also presents 
properties of an ORCC[24]. These channels are known to: 1) be activated upon excision 
of the cell membrane from the intact cell and after strong depolarization[69], 2) have 
single-channel conductance between 30-70 pS, 3) have the halide sequence of I- > Cl- > 
Br-, 4) have a outwardly rectifying current/voltage (I/V) relation and 5) be activated by 
cAMP and PKA and through extracellular UTP[70–72]. 
Interestingly, anoctamins are even able to interact with each other influencing their 
function. Ano 9 and Ano 10 both suppress baseline Cl- conductance (maintained by Ano 
6 among other proteins) as well as ATP-induced and ionomycin-induced (produced by 
Ano 1) anion conductances. Also co-expression of Ano 9 with Ano 1 showed to inhibit 
Ano 1 activity [66, 73]. 
Another difference between anoctamins is cell localization. Ano 1, 2, and 6 are well 
expressed in the PM, while Ano 5, 7, 8, 9, and 10 were much less membrane localized, 
which probably has a substantial impact on the current size[65, 74]. 
 
1.6.4 Interaction between CFTR and Anoctamins 
 
As previously referred CFTR can interact with several proteins, among them are 
Anoctamins. 
In bovine pulmonary artery endothelial (CPAE) cells[17], Xenopus oocytes[44], and 
mouse parotid acinar cells[18] expression of CFTR reduces calcium-activated chloride 
currents. Even more interesting, was found that these currents were increased in airway 
epithelial cells from CF patients and CF mouse models[19, 75, 76]. 
Being Ano1 the major component of CaCC is the anoctamin that showed more 
relation with CFTR. While studying the effects of variations of the extracellular pH on 
CFTR, Kunzelmann and co-workers observed that endogenous Ca2+- dependent Ano1 
Cl- currents present in Xenopus oocytes are activated by extracellular protons, however, 
only when CFTR is expressed[13]. 
Other recent data suggests that Ano1 currents are attenuated by additional 
expression of CFTR and totally abrogated when additional CFTR is activated. CFTR 
currents also revealed to be attenuated by overexpression of Anoctamin 1[16], revealing 
an inverse relationship. 
On experiments performed on Ano1 knockout mice models was found a reduced 
particle transport in their tracheas, suggesting impaired mucociliary lung clearance in 
these animals[43, 67]. In fact, they may develop a lung phenotype that is similar to that of 
CF patients[43, 77].  
Although CaCCs appear enhanced in CF, it is nevertheless not able to compensate 
for defective CFTR. This is explained by an only small contribution of CaCC to human 
airway Cl− secretion and by the fact that activation of CaCC is largely transient, in 
contrast to the permanent CFTR-dependent Cl− secretion. So a deeper knowledge of 
CaCC function, activation and mechanism of interaction with CFTR is absolutely 
necessary.  
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Another anoctamin that seems to interact with CFTR is Ano6 (TMEM16F). Recently 
was found that TMEM16F is the crucial component of ORCC single-channel and whole-
cell currents in airway epithelial cells and Jurkat T lymphocytes, being activated during 
membrane depolarization or apoptosis[24]. For a long time now ORCC is known to be 
regulated by CFTR, such that in CF ORCC is unresponsive to cAMP-dependent stimuli[69, 
70]. Schwiebert and colleagues proposed that CFTR regulates ORCCs by triggering the 
transport of ATP out of the cell, stimulating ORCCs afterwards through a purinergic 
receptor-dependent signaling mechanism[21], though this model is not fully accepted and 
the ATP transport through CFTR has not been well proven. 
However, just now the molecular identity of ORCC came to light with the discovery of 
Anoctamins and Ano6 whose ORCC currents showed to be augmented by CFTR in A549 
airway epithelial cells[24]. 
It was also proposed that cAMP/PKA-dependent activation of chloride transport by 
CFTR and ORCC requires mobilization of a multi-protein complex involving the calcium 
binding proteins annexin 2, S100A10 and the immune suppression target and 
phosphatase calcineurin A. Disruption of the annexin A2-S100A10/CFTR complex in wild 
type cells significantly attenuates CFTR function and obtunds CFTR- regulated ORCCs 
that generate ORCC-mediated currents[78]. 
These data suggest a possible interaction between CFTR and Ano6, whether physical 
or purely functional is still unknown. 
It’s possible that CFTR and TMEM16A/F may interact directly or through scaffold 
proteins such as NHERF1 or other PDZ-domain proteins. NHERFs are majorly localized 
at the cell surface, so it is normal that most of NHERF targets are membrane proteins, 
ion transporters, and receptors, specifically G protein-coupled receptors (GPCRs). The 
interaction between CFTR and other ion channels/transporters and NHERF1 is already 
well established, and is known that NHERF-1-bound CFTR is more efficiently 
phosphorylated by an ezrin-bound PKA leading to the increasing of chloride transport[79–
81]. Some recent studies demonstrating that CFTR translocates Gq-coupled receptors to 
the PM of Xenopus oocytes allowing for Ca2+ increase and activation of TMEM16A[13, 43] 
are a reinforcement of the CFTR/Anoctamins interaction through PDZ binding proteins 
hypothesis. Nonetheless, more studies need to be performed to confirm or discard this 
assumption. 
Summarizing, in the presence of wild-type CFTR, parallel activation of CFTR and 
outwardly rectifying anoctamin 6 Cl- channels is observed, while the Ca2+-activated 
anoctamin 1 Cl- channel is inhibited. In contrast, in CF cells, CFTR is 
missing/mislocalized and the outwardly rectifying chloride channel is attenuated while 
anoctamin 1 currents appear upregulated. 
These evidence for CFTR/Anoctamins interaction allow us to think in terms of possible 
alternative pharmacological targets for cystic fibrosis that lead to a more sustained Cl- 
secretion in the patients. However a more detailed knowledge about the relationship 
between these two protein families is needed. 
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2 Objectives 
 
The aim of the present work was to study the type of interaction between CFTR and 
Anoctamins, more specifically Ano1 and Ano6 as well as to assess the significance of 
both WT- and F508del-CFTR on these two anoctamins genesis, trafficking and function. 
There were already some evidences of a functional relationship, however the extent of 
this interaction and the possibility of communication on other levels are still unknown.  
In order to achieve this goal several milestones were elaborated, namely: 
- To evaluate Ano1, -6, -9 and -10 endogenous expression on cells expressing 
either WT-CFTR or F508del-CFTR by semi-quantitative PCR; 
- To evaluate Ano1 and Ano6 cell localization by immunofluorescence assays, 
when co-expressed with WT- and F508del-CFTR; 
- To evaluate direct interaction between CFTR/Ano1 and CFTR/Ano6 using co-
immunoprecipitation technique; 
- To evaluate the role of PDZ BD on CFTR/Ano1 possible physical interaction 
through co-immunoprecipitation of CFTR/Ano1 PDZ BD mutant; 
- To study the influence of WT-CFTR and F508del-CFTR on Ano1 and Ano6 
currents and compare with previously existent data. 
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3 Materials and Methods 
 
3.1 Cell Culture 
 
3.1.1 Mammalian Cell Lines and Culture Conditions 
 
Cystic Fibrosis Bronchial Epithelial (CFBE41o-) cells[82], from now on referred as just 
CFBE cells, overexpressing WT-CFTR or F508del-CFTR with an mCherry tag and under 
tet-on promoter induction. Cells were cultured in MEM, GlutaMAXTM (Life Technologies 
- Gibco®, 41090-036) media supplemented with 10% fetal bovine serum (FBS; Life 
Technologies - Gibco®, 10437-028) and 1% Penicillin-Streptomycin (Life-Technologies, 
15140148), in plastic flasks or plates coated with LHC basal medium (Life Technologies, 
12677-019), 0.1mg/mL bovine serum albumin, fraction V (Roche Applied Science, 
10735078001), 29μg/mL collagen from rat tail (Roche Applied Science, 11179179001) 
and 10μg/mL fibronectin (Roche Applied Science, 10838039001). 
 
HeLa Kyoto cells[83, 84] and Human Embryonic Kidney (HEK293) cells were cultured in 
DMEM, GlutaMAXTM (Life Technologies - Gibco®, 10566-016) media supplemented with 
5% FBS and 1% Penicillin-Streptomycin. 
 
Baby hamster kidney (BHK) cells[85] stably expressing either WT- or F508del-CFTR 
proteins were cultured in DMEM/F-12, GlutaMAXTM (Life Technologies - Gibco®, 10565-
018) supplemented with 5% FBS and 500 µM methotrexate (Merck Millipore, 454126-
100MG or Sigma-Aldrich, M8407-100MG). 
 
All cell lines were cultured in an incubator with humidified atmosphere of 5% CO2 at 
37°C. 
 
3.1.2 Transfections 
 
All transfections were performed using LipofectamineTM2000 transfection reagent 
(Invitrogen, 11668-019) according to the manufacture’s guidelines. All experiments were 
executed after 48 to 72 hours transfection. 
 
 
3.2 Molecular Biology 
 
3.2.1 Plasmid vectors 
 
The FLAG-tag was inserted into Ano1, 6 and 9 which were already fused with yellow 
fluorescent protein (YFP), cyan fluorescent protein (CFP) and green fluorescent protein 
(GFP) at the C-terminus and cloned into pcDNA3.1 vectors. See cloning details on 
section 3.2.5. Afterwards, these vectors were transfected into HeLa Kyoto and HEK293 
cells in order to evaluate the mutagenesis success. 
For the immunocytochemistry and patch clamp techniques BHK WT- and F508del-
CFTR cells were transfected with the bicistronic pIRES vectors encoding for human 
Anoctamin 1 and 6 fused with GFP at the C-terminus and for CD8 
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pcDNA3.1 vectors carrying cDNA for human Ano1 and Ano6 GFP at the C-terminus 
and bicistronic pIRES vector encoding for human Anoctamin 1 single-mutated on the 
PDZ BD (L982A) and for CD8 were transfected into BHK cells overexpressing WT- and 
F508del-CFTR for the co-immunoprecipitation assays. 
 
Maps and cloning schemes can be found on section 8 Appendices. 
 
3.2.2 Competent bacteria production and transformation 
 
The bacterial strain used for cloning and DNA amplification was XL1-Blue 
(Stratagene, La Jolla, CA, USA), which is tetracycline resistant. 
Bacteria were plated in LB-agar medium supplemented with tetracycline and a single 
colony was used to inoculate a small volume of LB medium overnight at 37°C with 
vigorous shaking (220 rpm). This pre-culture was then used to inoculate at 1/100 dilution 
a larger volume of LB medium, typically 100 ml, which was also grown at 37°C (220 rpm) 
to final concentration of 5 × 107bacteria/ml (corresponding to an absorbance of 0.3 at 
600 nm). Bacteria were transferred to ice and pelleted by centrifugation (1000xg for 15 
minutes at 4°C). The bacterial pellet was then ressuspended, incubated on ice for 15 
minutes in 33mL RF1 buffer (100 mM RbCl, 50mM MnCl2, 30 mM KCH3COO pH 7.5, 10 
mM CaCl2, 15% (w/v) glycerol, pH 5.8; all from Sigma-Aldrich, St. Louis, MO, USA) and 
re-pelleted by centrifugation (1000xg for 15 minutes at 4°C). This second pellet was 
ressuspended and incubated on ice for 15 minutes in 8.3mL RF2 buffer (10 mM MOPS, 
10mM RbCl, 75mM CaCl2, 15% (w/v) glycerol, pH 6.8; all from Sigma-Aldrich). 200 μl 
aliquots were then rapidly frozen with liquid nitrogen and stored at -80°C. 
To perform bacteria transformation, an aliquot of competent bacteria was incubated 
with 5-20 ng of plasmid DNA for 30 minutes on ice. Afterwards they were submitted to 
heat shock, 1 minute 30 seconds at 42°C followed by 2 minutes on ice, and grown in LB-
media without antibiotic for 1h at 37°C with shaking (300 rpm), in order to allow antibiotic 
resistance to be expressed. 
The bacteria were then centrifuged for 2 minutes at 6000 rpm, the pellet was 
ressuspended in the few rests of supernatant and plated on LB-agar plates with 
100µg/mL of selection antibiotic (ampicillin; Sigma-Aldrich, A0166-5G) which were 
incubated overnight at 37°C. 
Finally, the transformed bacteria were grown in LB-media supplemented with 
100µg/mL of selection antibiotic (ampicillin) and plasmid DNA was extracted. Clones 
were stored in liquid LB-media supplemented with 15 % (w/v) glycerol (Sigma-Aldrich, 
G5516-500ML) at -20°C. 
 
3.2.3 DNA extraction 
 
Small, medium and big scale plasmid DNA were purified with NZYMiniprep kit 
(NZYtech, MB01001), NucleoBond® Xtra Midi kit (Macherey-Nagel, 740412.50) and 
NZYMaxiprep kit (NZYtech, MB0510), respectively accordingly with manufacturer’s 
guidelines. 
DNA concentration was afterwards determined by measurement of absorbance at 
260nm using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, 
USA) and its purity was evaluated by assessment of the ratio A260/A280. Only DNA with 
a ratio above 1.8 was considered pure enough for further use. 
 
3.2.4 DNA sequencing 
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The sequencing reactions were outsourced to StabVida, by Sanger method and using 
BigDye Terminator 3 (Applied Biosystems) and analysed in an ABI 3730XL sequencer 
(Applied Biosystems). Sequencing primers used for Ano1 plasmids sequencing were 
ANO1 seq1_F (forward primer, sequence 5’-GTGGCTGAGCACAGGC-3’), ANO1 
seq2_F (forward primer, sequence 5’-CTTCATGGAGCACTGG-3’), ANO1 seq3_F 
(forward primer, sequence 5’-CTGAAGCTGAAGCAGC-3’), ANO1 seq4_FP_F (forward 
primer, sequence 5’-GGAGCGGCAGAAGG-3’); for Ano6 the primers used were ANO6 
seq1_F (forward primer, sequence 5’-GGGATCAACAGAC-3’), ANO6 seq2_F (forward 
primer, sequence 5’-GGCTCTCGGTGTTC-3’), ANO6 seq3_F (forward primer, 
sequence 5’-GAGCATGGCAGCCC-3’) and ANO6 seq4_F (forward primer, sequence 
5’-CATGAGAATCACC-3’); for Ano9 the primers used were ANO9 seq1_F (forward 
primer, sequence 5’-CTGAGCGGATTCTC-3’), ANO9 seq2_F (forward primer, 
sequence 5’-GAGTGCCACGCCAG-3’) and ANO9 seq3_F (forward primer, sequence 
5’-GCCATCCGCCTG-3’). All sequencing primers were obtained through StabVida. 
The resulting sequences were analysed using the software Geneious 
(http://www.geneious.com/) by comparison with the reference human Ano1, Ano6 and 
Ano9 sequences (NCBI reference sequence NM_018043.5, NM_001025356.2 and 
NM_001012302.2, respectively). 
 
3.2.5 Mutagenesis 
 
FLAG tag (5’-GATTACAAGGATGACGACGATAAG-3’) was introduced in frame into 
Ano1, Ano6 and Ano9, already fused with fluorescent proteins and cloned into pcDNA3.1 
(see templates on section 8 Appendices), using KOD Hot Start DNA Polymerase Kit 
(Novagene, 71086-3) with partially complementary pairs of mutagenic primers presented 
on Table 3.2. Primers were designed with the software PrimerX 
(http://www.bioinformatics.org/primerx). The mutagenesis reaction is a regular PCR 
reaction with the programs described on Table 3.1.  
After confirming the DNA amplification by agarose gel electrophoresis, the PCR 
products were incubated, for 1h, with DpnI (Invitrogen, 15242-019), a restriction 
enzyme that specifically hydrolyzes methylated and semi-methylated DNA, therefor 
degrading the non-amplified DNA.  
The resulting non-degraded DNA was used to transform competent bacteria (see 
section 3.2.2) and then the DNA was extracted as described on section 3.2.3. 
To assess for correct DNA content, 1 µg of each plasmid was digested by the 
restriction enzymes PstI (New England Biolabs, R0140) and SspI (New England Biolabs, 
R0132) for 1 hour at 37°C and also sent for DNA sequencing as described on section 
3.2.4. 
All the plasmid maps can be found on section 8. 
 
 
Table 3.1 – PCR programs for mutagenesis 
 
Template 
Temperature 
(°C) 
Time 
Number of 
cycles 
Ano1 eGFP 
Ano1 YFP 
Ano1 CFP 
95 2min 
23 
95 20sec 
56 10sec 
70 4min 
Ano6 eGFP 
95 2min 
23 
95 20sec 
48 10sec 
70 4min 
Ano9 eGFP 95 2min 23 
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95 20sec 
53 10sec 
70 4min 30sec 
 
 
Table 3.2 – Primers for FLAG-tag cloning 
 
 FLAG-tag insertion primers 
Template Forward Reverse 
*Ano1 
eGFP 
5’-GAGATGTGTGACCAGAGACAC 
GATTACAAGGATGACGACGATAAG 
AATATTACCATGTGCCCGCTTTG-3’ 
 
5’-CAAAGCGGGCACATGGTAATATT 
CTTATCGTCGTCATCCTTGTAATC 
GTGTCTCTGGTCACACATCTC-3’ 
 
*Ano1 YFP 
*Ano1 CFP 
**Ano6 
eGFP 
5’-CTGATATTGGTGGCAAGATC 
GATTACAAGGATGACGACGATAAG 
ATAATGTGTCCTCAGTGTG-3’ 
5’-CACACTGAGGACACATTAT 
CTTATCGTCGTCATCCTTGTAATC 
GATCTTGCCACCAATATCAG-3’ 
**Ano9 
eGFP 
5’-GGAGATCTGTGAGGCCCAC 
GACGATTACAAGGATGACGACGAT
AAGATCCTCATGTGTCCCCTCGGC
G-3’ 
5’-CGCCGAGGGGACACATGAG 
GATCTTATCGTCGTCATCCTTGTAAT
CGTCGTGGGCCTCACAGATCTCC-3’ 
* Primers provided by Dr. Rainer Schreiber (University of Regensburg) 
** Primers obtained by HPLC-purification through Thermo Scientific 
 
3.2.6 RNA extraction, DNaseI treatment, reverse transcription and semi-
quantitative PCR 
 
CFBE mCherry-WT- and mCherry-F508del-CFTR expressing cells were culture on 
p35mm dishes (Greiner bio-one, 627160), induced to express CFTR with 1 µg/mL 
doxycycline for 24 hours and stimulated for channel activation with 100 µM IBMX 
(competitive nonselective phosphodiesterase inhibitor that leads to reduction of cAMP 
degradation) and 2 µM FSK (activates adenylyl cyclase which leads to higher cAMP 
levels). Total RNA was extracted by adding 1ml / dish of Trizol (Invitrogen, 15596-026). 
The cells were then lysed directly in the culture dishes by pipetting them up and down 
several times and collected. Following homogenization, the lysates were centrifuged at 
12,000xg for 10 minutes at 4°C, the clear supernatants were transferred to a new tube 
and incubated at room temperature for 5 minutes. Afterwards 0.2mL of chloroform were 
added to each sample and they were vigorously shaken by hand for 15 seconds and left 
to incubate at room temperature for 3 minutes. After centrifuge at 12000xg for 15 minutes 
at 4°C, the colorless upper aqueous phase formed, containing the RNA, was collected 
and incubated with 0.5 mL of 100% isopropanol per sample, at room temperature for 10 
minutes. Another centrifugation at 12000xg for 10 minutes at 4°C was performed to 
obtain the RNA pellet. Finally, the pellets were washed with 1mL of 75% ethanol per 
sample, vortexed briefly, centrifuged at 7500xg for 5 minutes at 4°C and the RNA pellets 
were left to air dry for 5-10 minutes. After drying the pellets were ressuspended in 10µL 
of RNase-free water and quantified using the Nanodrop 2000 spectrophotometer 
(Thermo Scientific, Waltham, MA, USA). 
The samples were then submitted to a DNaseI treatment to degrade any DNA 
contamination in a procedure executed all on ice. 500 ng of RNA from each sample were 
added to a tube previously filled with RNase-free water and 0.5 µL of (10x) Reaction 
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Buffer (Invitrogen, 18068015) and afterwards 0.5 µL of DNaseI (1U/µL; Invitrogen, 
18068015) was added (final volume of 5 µL). The mixtures were subsequently incubated 
at 37ºC for 15 minutes, to be at the enzyme optimal temperature condition, and then the 
reaction was stopped by adding 0.5 µL of the enzyme inhibitor EDTA (25 mM; Invitrogen, 
AM9260G) and incubating the samples at 65°C for 15 minutes, to heat inactivate DNaseI. 
Finally, the samples were placed on ice for 1 minute and used to generate cDNA by 
reverse transcription. 
In order to obtain cDNA, the previous samples (5.5 µL) were mixed, on ice, with 0.5 
µL of a random hexamer primer (Invitrogen, N8080127), 0.5 µL of a dNTP mix (final 
concentration 0.5 mM; Invitrogen, 18427-013) and 1.5 µL of RNase-free water. The mix 
was incubated at 65 °C for 5 minutes, next chilled on ice for at least 1 minute and finally 
the reverse transcriptase mixture (1µL of 10x Reaction Buffer (NZYtech, MB0830); 0.5µL 
of NZY Ribonuclease Inhibitor (NZYtech, MB0840) and 0.5µL of NZY M-MuLV Reverse 
Transcriptase (200U; NZYtech, MB0830)) was added. After gently mixing and briefly 
centrifuge, the samples were incubate first at 25°C for 10 minutes and second at 37 °C 
for 50 minutes. The reaction was inactivated by heating at 70 °C for 15 minutes. 
CFBE WT- and F508del-CFTR cDNAs were used to quantify for Ano1, Ano6, Ano9 
and Ano10 endogenous expression by semi-quantitative PCR. A standard PCR was 
performed using the programs and the primers displayed on Tables 3.3 and 3.4, 
respectively. Samples were retrieved at specific cycles in order to determine the log 
phase (and avoid saturation) of cDNA amplification for all the anoctamins studied and 
after compare their expression by performing another standard PCR with the same 
number of cycles for each, inside the log phase. The detection of actin confirmed the 
sample viability and success of RNA extraction and cDNA production. 
After running all the PCR products on a 2% agarose DNA gel, using Red Safe 
(Chembio, 21141) to stain the DNA, the samples were quantified using the software FIJI 
(http://fiji.sc/Fiji). 
 
Table 3.3 – Standard PCR program 
 
Template 
Temperature 
(°C) 
Time 
Number of 
cycles 
Ano1 
94 5min 
Samples 
retrieved at 29, 
31, 33, 35, 37 
and 39 
94 30sec 
60 30sec 
72 1min 
72 5min 
Ano6 
94 5min 
Samples 
retrieved at 27, 
29, 31, 33, 35 
and 39 
94 30sec 
60 30sec 
72 1min 
72 5min 
Ano9 
94 5min 
Samples 
retrieved at 29, 
31, 33, 35, 37 
and 39 
94 30sec 
56 30sec 
72 1min 
72 5min 
Ano10 
94 5min 
35 
94 30sec 
60 30sec 
72 1min 
72 5min 
 
Table 3.4 – Primers to test for anoctamin expression 
 Anoctamin expression testing primers 
Template Forward Reverse 
Ano1 5’-CGACTACGTGTACATTTTCCG-3’ 5’- GATTCCGATGTCTTTGGCTC-3’ 
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Ano6 5’- GGAGTTTTGGAAGCGACGC-3’ 5’- GTATTTCTGGATTGGGTCTG-3’ 
Ano9 5’- GCAGCCAGTTGATGAAATC-3’ 5’- GCTGCGTAGGTAGGAGTGC-3’ 
Ano10 5’-GTGAAGAGGAAGGTGCAGG-3’ 5’-TCATCGTTTCAAAAGCCAACT-3’ 
 
All primers were provided by Dr. Rainer Schreiber (University of Regensburg). 
 
 
3.3 Protein Analysis 
 
3.3.1 Immunocytochemistry 
 
For the live-cell imaging microscopy, BHK parental, WT- and F508del-CFTR were 
grown on cover-slips and transfected with pIRES Ano1 eGFP CD8 and pIRES Ano6 
eGFP CD8. After two days, cells were incubated, for 10 minutes in the dark at room 
temperature, with a lipid marker (lissamine rhodamine B sulfonyl (ammonium salt)), with 
emission frequency in the red area of the visible spectrum (Avanti Polar Lipids, Inc, 
810150C), diluted to 1µM in Ringer solution (145mM NaCl, 0.4mM KH2PO4, 1.6mM 
KH2PO4·3H2O, 5mM glucose; 1mM MgCl2·6H2O, 1.3mM Calcium-D gluconate 
anhydrous) and examined under an ApoTome Axiovert 200M fluorescence microscope 
(Zeiss, Göttingen, Germany). Previously to incubation some cells were trypsinized and 
seeded on Poly-L-Lysine cover slips in order to reduce lipid marker attachment to the 
cover slip between the cells (referred when was the case). 
The fluorescence intensities were quantified by the software Axiovision from Zeiss 
(http://microscopy.zeiss.com/microscopy/en_de/products/microscope-
software/axiovision-for-biology.html) using images taken with the same exposure time to 
allow the comparison and using ApoTome. 
HeLa Kyoto cells were grown on 8-well Lab-tek® chamber slide (Sigma-Aldrich, 
C7057) and transfected with pcDNA3.1 Ano1 FLAG eGFP, YFP and pcDNA3.1 Ano9 
FLAG eGFP and further tested for recognition of the FLAG sequence inserted into the 
anoctamins (see section 3.2.5) by performing the immunostaining with anti-FLAG mouse 
IgG1 Ab (Sigma-Aldrich, F3165). 
For cell immunostaining, the Lab-tek was rinse three times with cold Phosphate Buffer 
Saline (PBS) and cells were incubated with the primary antibody anti-flag mouse in a 
1:500 dilution using PBS supplemented with 1% bovine serum albumin (BSA) for 1 hour 
at 4°C. The Lab-tek was once again washed three times with cold PBS and cells were 
fixed with 2% paraformaldehyde for 15 minutes at room temperature. Cells were 
thoroughly washed with PBS to remove any leftover of the fixing solution and afterwards 
incubated with the secondary antibody Alexa Fluor 568 Donkey Anti-Mouse IgG (Life 
Techologies, A10037) in a 1:500 dilution for 1 hour. The cells were again rinsed three 
times with PBS and Lab-teks were mounted with Vectashield mounting medium (Vector 
Laboratories, H-1000) containing DAPI (Sigma-Aldrich, D9542) and sealed. 
The stainings were observed in a Zeiss Axiovert 200M microscope (Zeiss, Jena, 
Germany) orin a Leica DMI4000B confocal microscope (Leica Microsystems, Wetzlar, 
Germany). 
 
3.3.2 Immunoprecipitation and Western Blot 
 
Cell lysis and protein collection: 
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Cells were grown on four 6-well plates and then lysed and protein was collected. They 
were washed twice with cold PBS and collected with the help of a scraper. Then a 
centrifugation at 5000 rpm for 5 minutes was executed and the resulting pellet was 
ressuspended in 150uL of Pierce IP Lysis Buffer (25mM Tris-HCL, 150mM NaCl, 1mM 
EDTA, 0.5% NP-40, 5% Glycerol; pH 7.4). Cell lysis was performed by using the 
mechanical strength of syringes (Disposable needles Sterican®, 24G violet and 27G 
grey). The lysate was centrifuged at 14000 rpm for 10 minutes at 4°C and the 
supernatant was collected. 
Protein quantification: 
The amount of protein in each lysate was quantified by the Bio-Rad Protein Assay 
Dye Reagent Concentrate kit (Bio-Rad, 500-0006EDU). The reagent was diluted 1:5 in 
distilled water and 1 mL was added to 8 BSA (Sigma-Aldrich, A4737) standards and to 
the samples to be measured (2 µL each sample). The solutions were incubated in the 
dark for 15 minutes and afterwards the absorbance was measured at 595 nm using the 
Novostar plate reader (BMG Labtech, Germany). 
Sample preparation: 
Pierce IP Lysis Buffer (25mM Tris-HCL, 150mM NaCl, 1mM EDTA, 0.5% NP-40, 5% 
Glycerol; pH 7.4) plus Protease Inhibitor (25x) (cOmplete, EDTA-free - 
Roche,11873580001) were added to 300-500 µg of protein samples up to 300 µL. Each 
sample was after incubated with antibody to immunoprecipitate either CFTR, Ano1 or 
Ano6 (1:200 dilution), overnight at 4°C with gentle shaking (antibodies are displayed on 
Table 3.5). Then 50µL of Protein G Agarose 50% slurry (Pierce, 20398) were added to 
each sample, followed by 3 hours incubation at room temperature, with gentle mixing. 
After incubation the samples were centrifuged for 3 minutes at 2500xg and the 
supernatant was discarded. The immune complexes were ressuspended with 500µL of 
IP Buffer (25mM Tris-HCl (pH 7.4), 150 mM NaCl - final pH 7.2) and gently mixed for 5 
minutes. This process was repeated two times more. To elute the immune complex the 
compound-bound resin was washed with 500µL of distilled water and the samples were 
centrifuged for 3 minutes at 2500xg. The complex-bound resin was after ressuspended 
in 30µL of Electrophoresis Loading Buffer (1x) (1.5M Tris-HCL (pH 6.8), 1.5% SDS, 5% 
Glycerol, 0.01% Bromophenol Blue). The samples were incubated for 30 minutes at 
room temperature and centrifuged for 3 minutes at 2500xg. The supernatant was 
collected to load into the SDS-Page gel. 
SDS-Page: 
The samples (50ug protein for input and 30uL for immunoprecipitation (IP) samples) 
were loaded into a 7.5% polyacrylamide stacking gel and 4% polyacrylamide separating 
gel and ran for 90 minutes at 110V 
Membrane Transfer: 
The proteins were transferred into a PVDF membrane (Merck Millipore, ISEQ00010) 
by performing a wet-transfer for 3 hours at 100V and 4º C. 
Immunoblotting: 
The membranes were blocked with 5% Non fat milk (NFM; Applichem, A0830,1000) 
in PBS-T (54mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4, 1.5mM KH2PO4, 0.1% Tween 
20 - pH 7.4) or TBS-T (50mM Tris, 150mM NaCl, 0.1% Tween 20), depending on which 
are the antibodies diluted, for 1 hour at room temperature followed by incubation with the 
primary antibody overnight at 4º C, with gentle shaking (see antibodies on Table 3.5). 
After washing the membranes with PBS-T or TBS-T they were incubated with the 
secondary antibody for 2 hours at room temperature (for the anti-goat Ab the incubation 
period is just 1 hour; see antibodies on Table 3.5). After washing, the signal for HRP 
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(horseradish peroxidase) was detected with Supersignal West Pico Chemiluminescent 
Substrate (1:1 proportion) (Thermo Scientific, 34077). 
 
Table 3.5 – Immunoprecipitation and western blot antibodies 
 Antibodies 
Antibodies 
dilution 
Dilution 
solution 
Immunoprecipitation 
anti-DOG1 (SP31) rabbit IgG monoclonal 
Ab (Cell Marque, CMC 24431031) 
1:200 
 
anti-DOG1/TMEM16A rabbit IgG 
monoclonal Ab (Novus Biologicals, 
NB110-90601) 
 
anti-CFTR 596 NBD2 domain mouse 
IgG2b monoclonal Ab (UNC Chapel Hill, 
A4) 
 
Anti-GFP goat IgG polyclonal Ab 
(Rockland, 600-101-215) 
 
Western Blot 1
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Anti-GFP goat IgG polyclonal Ab 1:3000 
1% NFM 
*TBS-T 
anti-DOG1 (SP31) rabbit IgG monoclonal 
Ab 
1:500 
3% NFM 
TBS-T 
anti-CFTR 596 NBD2 domain mouse 
IgG2b monoclonal Ab 
1:2000 
1% NFM 
**PBS-T 
anti-actin rabbit polyclonal Ab (Sigma-
Aldrich, A2066) 
1:1000 
1% NFM 
***PBS-T 
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anti-mouse IgG HRP goat (Leinco 
Technologies, M114) 
1:5000 1% NFM 
anti-rabbit IgG HRP goat (Acris, 
R1364HRP) 
1:10000 1% NFM 
anti-goat IgG1, F(ab’)2 HRP donkey 
(Santa-Cruz, sc:3851) 
1:5000 5% NFM 
* TBS-T (50mM Tris, 150mM NaCl, 0.1% Tween 20) 
** PBS-T (8.1mM Na2HPO4, 1.5mM KH2PO4, 54mM NaCl, 2.7mM KCl, 0.1% Tween 20, pH 7.4) 
*** PBS-T (8.1mM Na2HPO4, 1.76mM KH2PO4, 137mM NaCl, 2.78mM KCl, 0.1% Tween 20) 
 
 
3.4 Functional Analysis 
 
3.4.1 Patch clamp 
 
To evaluate Ano6 functionality after FLAG-tag cloning patch clamp assay was 
performed. HEK293 were grown on glass coverslips and transfected with pcDNA3.1 
Ano6 FLAG eGFP and pIRES CD8. The membrane receptor CD8 allows for the 
identification of the transfected cells by binding to Dynabeads CD8 (Invitrogen, 11147D). 
After 48 hours cells were patched on the stage of an inverted microscope (IM35, Zeiss) 
in a continuously perfused bath with Ringer solution (145mM NaCl, 0.4mM KH2PO4, 
1.6mM K2HPO4, 5mM glucose, 1mM MgCl2, 1.3mM Ca-gluconat, pH 7.4). Patch pipettes 
were filled with a solution containing 95mM K-gluconat, 30mM KCl, 1.2mM NaH2PO4, 
4.8mM Na2HPO4, 5mM glucose, 2.38mM MgCl2, 1mM EGTA, 0.726mM Ca-gluconat, 
with freshly added ATP (3 mM) and pH adjusted to 7.2. Patch clamp experiments were 
done in the fast whole-cell configuration. HEK cells’ Vm were clamped in steps of 20 mV, 
1s each, from -100 mV to +100 mV relative to the resting potential. Currents and voltages 
were recorded using a patch clamp amplifier EPC 9 and PULSE software (HEKA, 
Lambrecht, Germany) as well as Chart software (AD-Instruments, Spechbach, 
Germany). 
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BHK WT- and F508del-CFTR cells were grown on coverslips and transfected with 
pIRES Ano1 eGFP CD8 and pIRES Ano1 L982A CD8. After 48 hours cells were used 
for patch clamping. The cells grown on coverslips were then mounted on the stage of an 
inverted microscope (IM35, Zeiss). The bath was perfused continuously with Ringer 
solution (145mM NaCl, 0.4mM KH2PO4, 1.6mM K2HPO4, 5mM glucose, 1mM MgCl2, 
1.3mM Ca-gluconat, pH 7.4) warmed at 37°C. Patch pipettes were filled with a solution 
containing 95mM K-gluconat, 30mM KCl, 1.2mM NaH2PO4, 4.8mM Na2HPO4, 5mM 
glucose, 2.38mM MgCl2, 1mM EGTA, 0.726mM Ca-gluconat, and pH adjusted to 7.2. 
When referred extracellular chloride concentration was reduced to 5 mM (5Cl-) and 
replaced by gluconate. CFTR channel stimulation was achieved by applying 100 µM 
IBMX plus 2 µM forskolin. Patch clamp experiments were done in the fast whole-cell 
configuration. BHK cells’ Vm were clamped in steps of 20 mV, 1s each, from -100 mV to 
+100 mV relative to the resting potential. Currents and voltages were recorded using a 
patch clamp amplifier EPC 9 and PULSE software as well as Chart software. 
Experiments performed by Lalida Sirianant. 
 
 
3.5 Statistical Analysis 
 
Student’s t-test for paired or unpaired samples as appropriate. P<0.05 was accepted 
as significant. 
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4 Results 
 
4.1 Endogenous expression of Anoctamins in CFBE cells overexpressing 
WT-CFTR and F508del-CFTR 
 
The basic aim of this work is to assess the influence of CFTR, both WT and F508del 
on the expression and trafficking of Anoctamins in order to better understand their 
relationship and the potential of Anoctamins as alternative pharmacological targets in 
CF. Hereupon, the first step was to study the endogenous expression of Ano1, -6, -9 and 
-10 in CFBE cells stably expressing either WT- or F508del-CFTR. This cell line was 
chosen because, being isolated from the bronchial epithelium of CF patients, these cells 
mimic very well the processes that occur in CF, although being an immortalized cell line. 
To achieve this goal, a semi-quantitative PCR was performed for the referred 
anoctamins, using cDNA obtained from CFBE mCherry-WT- and F508del-CFTR cells. 
In order to compare gene expression/mRNA levels, the log phase of cDNA 
amplification was determined by performing a standard PCR and collecting samples at 
different amplification cycles (Figure 4.1).  
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Figure 4.1 – PCR for detection of endogenous expression of a) Ano1, b) Ano6, c) Ano9, d) actin and e) 
Ano10 in CFBE mCherry-WT- and F508del-CFTR cell lines. M stands for marker, (+) for positive control and 
(-) for negative control. 
 
The first observation was that Ano10 is not expressed in these cells (Figure 4.1 e) 
and because of this the semi-quantitative procedure was not executed for its detection. 
After doing the PCR it was possible to infer right away that anoctamins are not express 
at the same level since they started to be detected at different cycles of amplification. 
However to be more precise and compare them at a non-saturated phase the band 
intensities were quantified by the software FIJI (Figure 4.2) and was concluded that Ano1 
log phase is between 33 and 38 cycles, for Ano6 is between 28 and 32 and Ano9 shows 
very different expressions between WT- and F508del-CFTR expressing cells, 
demonstrating a shared log phase between 34 and 36 cycles. This conclusion made it 
very difficult to compare between anoctamins’ expression inside the same cell line at the 
same cycle. However, it is possible to suggest that Ano6 is clearly the more expressed 
anoctamin on both CFTR expressing cell lines, reaching the amplification plateau much 
sooner than the others. Ano1 and Ano9 expression seems to be similar on WT-CFTR 
expressing cells but on ΔF cells Ano1 appears to be more expressed than Ano9. 
Nonetheless, the most important thing was to compare each anoctamin’s expression 
between cells lines and for that a PCR was performed for each anoctamin at a cycle 
inside the amplification log phase and the same for both CFBE WT-CFTR and CFBE 
F508del-CFTR cDNA templates (Figure 4.3). 
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Figure 4.2 – Assessment of log phase of anoctamins’ PCR amplification. 
 
 
 
 
Figure 4.3 – PCR for quantification of anoctamins endogenously expressed in CFBE mCherry-WT- and 
F508del-CFTR cells. a) DNA agarose gel with the PCR products resulting from the amplification of Ano1 (33 
cycles), -6 (29 cycles), -9 (36 cycles) and -10 (40 cycles), using as template the cDNA from CFBE WT- (WT) 
and F508del-CFTR (ΔF) expressing cells. c) Quantification of PCR product by assessment of band intensity. 
Mean + SEM, n = number of semi-quantitative PCRs performed. *significant difference in gene expression 
(paired t-test) with p<0.05, # with p<0.01. 
 
Both Ano1 and Ano6 appear to be significantly more express in WT-CFTR expressing 
cells than in ΔF cells. Also Ano9 is much more express in WT than in F508del-CFTR 
cells, however here the statistically significant level was not reached (Figure 4.3). ΔF-
CFTR expressing cells showed a very consistent low level of Ano9 expression, but CFBE 
WT-CFTR cells, although always presenting a much higher expression level, the mRNA 
levels per se were not so similar in the compared cells (maybe a higher n would soften 
this difference). 
The obtained results suggest a CFTR influence on anoctamins’ expression, because 
the presence of its WT form seems to correlate with higher mRNA levels of Ano1, -6 and 
-9 through a process that appears to be impaired in CF. 
However, to completely discard any doubt about the suggested role of CFTR the 
anoctamins’ mRNA levels need to be fully quantified on both cell lines through, for 
example, a much more potent real-time PCR assay. 
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4.2 Cell localization of Ano1 and Ano6 on BHK WT- and F508del-CFTR 
overexpressing cells 
 
After assessing for CFTR influence on anoctamins’ expression the effect of this 
proteins on anoctamins’ trafficking was studied. From now on this work will only focus on 
anoctamin 1 and anoctamin 6 because they are the ones which already showed some 
evidence of interaction with CFTR at a functional level. Therefore, cell localization of 
Ano1 and Ano6 was evaluated in presence of either WT- or F508del-CFTR. To 
accomplish this, BHK cell lines were used instead of CFBE cells because the last ones 
are very difficult to transfect allowing only very low transfection yields, as it happens for 
all epithelial cell lines[86]. Parental BHK and the ones overexpressing the CFTR forms, 
were transfected with either Ano1 or Ano6 tagged with eGFP and their cell localization 
was appraised through the fused fluorescent protein. 
 
 
 
 
 
 
 
 
Figure 4.2 – Immunocytochemistry (live imaging) of eGFP tagged Ano1 (green) when transiently 
overexpressed in a) parental BHK cells, b) BHK WT-CFTR and c) BHK F508del-CFTR after 10 minutes 
stimulation with 100 µM IBMX / 2 µM Forskolin. Scale=10 µm 
 
Ano1 was majorly detected on the cell surface for all the transfected cell lines, 
demonstrating an overlapping signal with the PM marker (lipid marker; Figure 4.2). Cell 
localization of Ano1 does not appear to be affected by the presence of CFTR since its 
localization is similar on parental and overexpressing CFTR cells. Also the expression of 
b) BHK WT-CFTR cell line 
Merge 
Lipid marker Merge 
a) Parental BHK cell line 
c) BHK F508del-CFTR cell line 
Ano1 (eGFP) Lipid marker Merge 
Lipid marker Merge Ano1 (eGFP) 
Lipid marker Ano1 (eGFP) Merge 
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both WT- and F508del-CFTR does not seem to interfere with Ano1 cell localization which 
shows to be identical on the two cell lines. Analogous results were obtained when CFTR 
was not stimulated with IBMX/F for channel activation (see section Appendix 8.10), 
suggesting that the activation process of CFTR has also no impact on Ano1 localization. 
Although the cell localization is similar, Ano1 fluorescence intensity on the cell 
membrane is notoriously different depending on cell line. It was observed that on cells 
co-expressing WT-CFTR and Ano1 the cell surface fluorescent signal was significantly 
higher than on F508del-CFTR expressing cells (Figure 4.3). This may suggest that CFTR 
has some influence on Ano1 cell surface expression but not localization since that it was 
similar on all cell lines.  
However, because this study is being executed on an overexpressing system we may 
be facing a variance in plasmid uptake and consequent 
expression. Being impossible to determine the number 
of plasmid copies incorporated by each cell, the 
possibility that BHK WT-CFTR are expressing more 
Ano1 because they integrated a higher number of 
plasmid copies cannot be discarded. So, to better 
understand and trust this result more experiments 
need to be performed. In order to lower this probability, 
double tagged anoctamin constructs were created by 
cloning a FLAG-tag into the anoctamins already fused 
with fluorescent proteins (for plasmid maps see section 
8). These constructs allow the quantification of the 
protein localized only on the cell surface (by detecting 
the FLAG-tag on the extracellular loop) which can after 
be normalized to the total amount of expressed protein 
(by measuring the eGFP signal), then eliminating the 
variance associated to these overexpressing systems. 
Some of these plasmids were already tested for anti-
FLAG antibody binding (anoctamins’ topology is not yet 
certain, being necessary to confirm if the FLAG 
sequence was actually cloned on an extracellular segment) and protein functionality after 
cloning (see appendix 8.10), but the experiments on CFTR expressing cell lines need 
yet to be done. 
 
The same experiments were performed in BHK cells, transiently expressing ANO6, 
as shown in the following images. 
 
 
  
a) Parental BHK cell line 
Figure 4.3 – Ano1 cell surface 
expression in transiently 
transfected BHK cells stably 
expressing WT- and F508del-
CFTR and parental CFTR. Mean 
+ SEM, n = number of cells 
measured. *significant membrane 
expression (paired t-test; p<0.05). 
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Figure 4.4 – Immunocytochemistry (live imaging) of eGFP tagged Ano6 (green) when transiently 
overexpressed in a) parental BHK cells, b) BHK WT-CFTR and c) BHK F508del-CFTR after 10 minutes 
stimulation with 100 µM IBMX / 2 µM Forskolin. Scale=10 µm 
 
Ano6 cell distribution is not as clear as for Ano1. It seems that is not only membrane 
localized but can also be found intracellular for all cell lines. Nevertheless, Ano6 appears 
to be more cell surface localized in the presence of F508del-CFTR than WT-CFTR. It 
was observed as well that cells co-expressing WT-CFTR and Ano6 had the tendency to 
die much more than cells expressing F508del-CFTR instead. This tendency still needs 
to be quantified by an apoptosis assay to allow further conclusions. 
Similar results were obtained when cells were not previously stimulated with the CFTR 
activators IBMX/F (see appendix 8.9). 
 
 
4.3 Interaction of Ano1 and Ano6 with CFTR 
 
The next step was to assess for a direct and physical interaction between CFTR-Ano1 
and -Ano6. To attain this a co-immunoprecipitation assay was performed for the referred 
proteins using lysates from BHK cells stably expressing either WT- or F508del-CFTR 
which were transiently expressing GFP tagged Ano1 and Ano6. 
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Figure 4.5 – Co-immunoprecipitation of CFTR and Ano1 eGFP. Ano1 eGFP and CFTR were detected using 
a GFP-antibody and the CFTR-antibody 596, respectively (input). Immunoprecipitation of beads only (no 
conjugated antibody) served as a negative control. a) Ano1 eGFP was co-immunoprecipitated after pull-
down of WT-CFTR using CFTR-Antibody 596 (right panel), and WT-CFTR was also detected in Ano1 eGFP 
pull-down, obtained using the GFP-antibody (left panel). b) No co-immunoprecipitation of Ano1 eGFP and 
F508del-CFTR was detected when pulling-down defective CFTR (right panel) or Ano1 eGFP (left panel). 
 
It was observed that Ano1 co-immunoprecipitate with WT-CFTR when pulling-down 
one or the other (Figure 4.5 a) and after comparing this result with the negative control 
lane (beads) sample contamination can be discarded, since it is completely clean. This 
outcome suggests that a direct and physical interaction between Ano1 and WT-CFTR is 
occurring. However, the same doesn´t appear to be true for F508del-CFTR. When the 
co-immunoprecipitation assay was performed for Ano1 and defective CFTR no co-
immunoprecipitation was observed in neither of the pull-downs (Figure 4.5 b). This may 
indicate that against what happens for WT, when F508del-CFTR is present it does not 
directly interact with Ano1, as expected, because the defective CFTR form is retained at 
the ER and does not migrate to the PM, where Ano1 is majorly localized. 
After noticing this result it was proposed that WT-CFTR and Ano1 may interact 
through a scaffold protein which binds to their PDZ binding domain. In order to test this 
hypothesis BHK cells expressing WT- and F508del-CFTR were transiently transfected 
with an Ano1 mutant on the PDZ domain (Ano1 L982A) and a co-immunoprecipitation 
assay was again performed. In order to fully compare the results and eliminate any 
possibility of GFP interfering with PDZ binding motif, this assay was also repeated for 
CFTR and Ano1 without the GFP tag. 
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Figure 4.6 – Co-immunoprecipitation of CFTR and Ano1. Ano1 and CFTR were detected using the 
TMEM16A (DOG1)-antibody and the CFTR-antibody 596, respectively (input). Immunoprecipitation of beads 
only (no conjugated antibody) served as a negative control. a) Ano1 was co-immunoprecipitated after pull-
down of WT-CFTR using CFTR-Antibody 596 (right panel), and WT-CFTR was also detected in Ano1 pull-
down, obtained using the TMEM16A-antibody (left panel). b) No co-immunoprecipitation of Ano1 and 
F508del-CFTR was detected when pulling-down Ano1 (left panel) but a signal was detected when F508del-
CFTR was pulled-down (right panel). 
 
Figure 4.7 – Co-immunoprecipitation of CFTR and Ano1 L982A. Ano1 L982A and CFTR were detected using 
the TMEM16A (DOG1)-antibody and the CFTR-antibody 596, respectively (input). Immunoprecipitation of 
beads only (no conjugated antibody) served as a negative control. a) Ano1 L982A was co-
immunoprecipitated after pull-down of WT-CFTR using CFTR-Antibody 596 (right panel), and WT-CFTR 
was also detected in Ano1 L982A pull-down, obtained using the TMEM16A-antibody (left panel). b) No co-
immunoprecipitation of Ano1 mutant and F508del-CFTR was detected when pulling-down Ano1 L982A (left 
panel) but a signal was detected when F508del-CFTR was pulled-down (right panel). 
 
As observed for Ano1 eGFP, Ano1 also seems to co-immunoprecipitate with WT-
CFTR (Figure 4.6 a). However anti-TMEM16A (DOG1) antibody appears to be detecting 
different maturation forms of Ano1 (Ano1 has 5 putative N-glycosylation sites) or is not 
specific for Ano1. The lower band is the one corresponding to the non-glycosylated form 
which is detected in the WT-CFTR pull down. When the Ano1 PDZ binding domain is 
single mutated both proteins still co-immunoprecipitate (Figure 4.7 a), suggesting that 
the interaction established between them is not achieved through their PDZ binding 
domains. 
The result obtained for Ano1 and F508del-CFTR is different from the one with Ano1 
eGFP instead. A signal was detected in the pull-down F508del-CFTR sample at the 
same level as the previously referred upper band on the Ano1 input (Figure 4.6 b, right 
panel), but when Ano1 is pulled-down no co-immunoprecipitation with CFTR is detected 
(Figure 4.6 b, left panel). An analogous situation was observed for co-
immunoprecipitation of Ano1 mutant and defective CFTR (Figure 4.7 b). After these 
observations it can be considered that the anti-TMEM16A antibody is not specific for 
Ano1 and it might be binding to other proteins. 
Ano6 interaction with CFTR was also assessed and the results suggest a direct 
interaction between the two since WT-CFTR co-immunoprecipitate with Ano6 and vice-
versa (Figure 4.8 a). Interestingly Ano6 appears to be present in two different levels of 
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maturation, the non-glycosylated form around 133 kDa and probably a glycosylated form 
detected at ≈160 kDa, and It seems that WT-CFTR interacts with both because similar 
to the input two bands for Ano6 were detected in the pull-down WT-CFTR sample (Figure 
4.8 a, right panel). This glycosylation hypothesis can be tested by previously digesting 
the sample with enzymes that cleave the glucose chains and then compare the western 
blot result for this sample with one not previously digested. No co-immunoprecipitation 
was detected between Ano6 and ΔF-CFTR. 
 
 
Figure 4.8 – Co-immunoprecipitation of CFTR and Ano6 eGFP. Ano6 eGFP and CFTR were detected using 
a GFP-antibody and the CFTR-antibody 596, respectively (input). Immunoprecipitation of beads only (no 
conjugated antibody) served as a negative control. a) Ano6 eGFP was co-immunoprecipitated after pull-
down of WT-CFTR using CFTR-Antibody 596 (right panel), and WT-CFTR was also detected in Ano6 eGFP 
pull-down, obtained using the GFP-antibody (left panel). b) No co-immunoprecipitation of Ano6 eGFP and 
F508del-CFTR was detected when pulling-down defective CFTR (right panel) or Ano6 eGFP (left panel). 
 
4.4 CFTR influence on Ano1 and Ano6 function 
 
The last goal was to evaluate the effect of WT- and F508del-CFTR on Ano1 and Ano6 
function. To achieve this BHK cells stably expressing WT- and F508del-CFTR were 
transiently transfected with Ano1 eGFP CD8 and whole-cell currents were measured by 
patch clamp. The experiments with Ano6 are still in progress. 
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Figure 4.9 – BHK WT- and F508del-CFTR stably expressing cells were transfected with Ano1 eGFP CD8 
and whole-cell currents were measured by patch clamp before and after replacement of extracellular chloride 
with impermeable gluconate (except of 5 mM; 5Cl-), using a voltage ramp protocol (-100mV – 100mV). a) 
BHK WT-CFTR Ano1 average whole-cell current density at 100 mV (on left) and current–voltage (I/V) 
relationships of resting currents and inhibited by 5Cl- (on right). b) The same as in a) but on BHK F508del-
CFTR cells. Mean ± SEM, n = number of cells measured, *statistically significant current inhibition (paired t-
test; p<0.05). 
 
Ano1 transiently expressing cells displayed a large conductance, that was inhibited 
when chloride was reduced to a 5 mM extracellular concentration and replaced by 
impermeable gluconate (5Cl-), indicating constitutively active Ano1 on both WT- and ΔF-
CFTR stably expressing cells (Figure 4.9). It remained unclear why Ano1 was 
spontaneously active when expressed in either WT-CFTR or ΔF-CFTR expressing BHK 
cells, without stimulation by Ca2+-increasing 
ionomycin. Further activation of cell currents by 
stimulation with ionomycin was not observed 
(data not shown). Due to this, activation of Ano1 
current depending on the stimulation of CFTR 
could not really be assessed in these cell lines. 
Moreover, cAMP (IBMX/FSK) dependent 
activation of WT-CFTR was largely reduced in 
Ano1-expressing cells (Figure 4.10). This, 
however, is probably because total whole cell 
currents were so large that they reached the 
limit of resolution which is due to technical 
reasons: when whole cell currents reach 10 nA, 
the impact of the serial pipette resistance 
becomes so large that the cells are no longer 
adequately voltage clamped. 
Moreover, an Ano1 mutant lacking the PDZ 
domain produced similar currents and similarly 
reduced IBMX/FSK induced WT-CFTR 
currents in WT-CFTR co-expressing BHK cells, 
suggesting that the PDZ domain of Ano1 is not 
required for proper membrane expression of 
Ano1 (Figure 4.10). 
As for Ano6 expression in WT-CFTR or 
F508del-CFTR expressing BHK cells, these 
experiments could not be finished within the 
given time. Moreover and as outlined above, 
Ano6 expression in WT-CFTR expressing BHK 
cells induced a strong apoptosis so that cells 
co-expressing both ion channels typically got 
b) BHK F508del-CFTR Ano1 
n=5 
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Figure 4.10 – Average current density of 
cells response to 100 µM IBMX and 2 µM 
forskolin stimulation. BHK WT- and 
F508del-CFTR stably expressing cells 
were transiently transfected with either 
Ano1 eGFP or Ano1 L982A (PDZ mutant) 
and whole-cell currents were measured by 
patch clamp before and after CFTR 
channel stimulation with IBMX/F, using a 
voltage ramp protocol (-100mV – 100mV). 
Mean ± SEM, n = number of cells 
measured, # statistically significant lower 
current activation when compared with 
WT-CFTR expressing cells (paired t-test; 
p<0.01). 
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lost during transfection. Subsequent experiments will now examine those cells at earlier 
time points after transfection. 
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5 Discussion 
 
This work follows the evidence on the literature about the calcium-activated chloride 
channel Ano1 and the outwardly rectifying chloride channel Ano6 functional relationship 
with CFTR. 
Ano1 function showed to be inhibited by the activation of both WT- and F508del-
CFTR, in more extent by the first than the second, when expressed in Xenopus 
oocytes[44]. Also endogenous CaCC currents were significantly reduced after expression 
of WT CFTR and activation of endogenous CFTR[16, 17]. On the other hand, whole-cell 
currents activated by IBMX and forskolin were significantly reduced in cells expressing 
both Ano1 and CFTR when compared with cells expressing only CFTR[16]. This negative 
relationship between these two proteins was already demonstrated in Xenopus oocytes, 
bovine pulmonary artery endothelium, and isolated parotid acinar cells, although the 
mechanism that leads to this is yet unknown[17, 18, 44, 54]. 
CFTR displays a regulatory effect on Ano6 as well. For a long time now CFTR has 
been implicated in the regulation of ORCC currents[21, 69], however only recently these 
ORCC were identified as Ano6 or at least majorly composed by it[24]. The ORCC currents 
produced by Ano6 showed to be significantly larger in cells expressing CFTR than in 
non-expressing cells[24]. 
Then, the main goals of this thesis were to understand CFTR influence on Anoctamin 
1 and -6 expression, trafficking and function always comparing these processes on WT-
CFTR expressing cell lines and on cells mimicking the CF environment by expressing 
the most common CFTR mutation, F508del-CFTR. 
 
 
5.1 CFTR influence on Anoctamins’ expression 
 
The first objective consisted on comparing the anoctamins’ endogenous expression 
on WT- and F508del-CFTR expressing cells. This study was performed on CFBE cells 
to better mimic the processes which occur in the lungs / bronchus in the presence of CF 
(when F508del-CFTR is expressed). 
The semi-quantitative PCR revealed Ano6 as the most expressed anoctamin between 
the ones tested (Ano1, -6, -9 and -10) and the non-expression of Ano10 by CFBE cells. 
It is known that Ano6, -1 and -9 are much expressed in human airways tissues[43], 
however in this human airway cell line there is a clear difference among expression 
levels, specially between Ano6 and the others on WT-CFTR cells and between all of 
them on F508del-CFTR cells. It would be interesting to see how this expression disparity 
is reflected on the cell currents and compare the function of the different anoctamins, for 
example by performing an Ussing Chamber assay. 
When comparing the anoctamins’ expression level between WT- and ΔF-CFTR stably 
expressing cell lines it was noticeable that WT cells express more Ano1 and Ano6 than 
F508del cells, although Ano9 also showed a big difference in mRNA levels, they were 
not statistically significantly higher when WT-CFTR was present, but this issue seems to 
be due to the low number of samples measured (3) and a higher n would probably reveal 
a significant difference among Ano9 expression levels. The next step should be to 
perform a real-time PCR to fully quantify these genes expression and to see if this 
stronger assay can also statistically distinguish anoctamins’ expression between WT- 
and F508del-CFTR expressing cells and then it will be possible to conclude with 
complete certainty that WT-CFTR regulates or is a component of the regulator machine 
that is behind anoctamins’s expression which is impaired in CF. 
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Thinking in terms of the already observed functional relationship between CFTR and 
anoctamins, the expression measured for Ano6 suggests that CFTR enhances its 
expression which is somehow in agreement with what was already seen for the functional 
relationship between them meaning that the bigger Ano6 function detected when CFTR 
is present can be due to its higher expression. 
Ano1 mRNA levels contradict a bit the negative functional interaction shared with 
CFTR, since it seems that WT cells are expressing more Ano1 than ΔF. This evidence 
may lead to the belief that because Ano1 mRNA levels are higher when WT-CFTR is 
present so the protein amount will be greater and currents will also be bigger than in 
F508del expressing cells. Nonetheless, it is proven that mRNA levels do not always 
completely correlate with the protein abundance and subsequent function. Regulatory 
processes play a substantial role after mRNA is made — like post-transcriptional, 
translational and protein degradation regulation —, controlling the steady-state protein 
abundances[87]. 
Ano9 relationship with CFTR is completely unknown, but as a protein that is mostly 
intracellular localized[66] the obtained results may suggest that the higher levels of 
defective CFTR that is imprisoned in the reticulum and therefor intracellular localized can 
be inhibiting Ano9 production and compensating its function. So it would be interesting 
to follow this with an immunofluorescence assay on cells either expressing WT- or 
F508del-CFTR and quantify the associated fluorescence to see the difference in terms 
of protein amount among WT and ΔF-CFTR expressing cells. 
 
 
5.2 CFTR effect on Ano1 and Ano6 cell localization 
 
Ano1 was mainly detected on the cell surface of overexpressing BHK cells, similar to 
what was previously observed in HEK293 cells[16]. The cell localization was the same in 
all WT- and ΔF-CFTR stably expressing cell lines as well as for parental whether 
stimulated with IBMX and forskolin or not, which suggests that CFTR is not influencing 
Ano1 trafficking to the cell membrane. However the membrane expression of Ano1, 
assessed through GFP-tag fluorescence intensity, is statistically different in cells 
expressing the two CFTR forms. In WT-CFTR expressing BHK cells the amount of Ano1 
at the cell surface is significantly higher than in F508del expressing ones. This result is 
in agreement with the one obtained by semi-quantitative PCR where it was seen a 
greater Ano1 gene expression in the presence of WT-CFTR than in F508del. So it can 
be proposed that Ano1 enhanced gene expression is reflected into a higher protein level 
which is majorly localized at cell surface in a process regulated through or by WT-CFTR. 
Nonetheless, this conclusion must be drawn with careful since the higher Ano1 PM 
expression in WT expressing cells may not only be due to CFTR but also because of 
artefacts caused by the working model. The experiments were done in an 
overexpressing system which carries a variance related with plasmid uptake and 
consequent expression. Being impossible to determine the number of plasmid copies 
incorporated by each cell, the possibility that BHK WT-CFTR are expressing more Ano1 
because they integrated a higher number of plasmid copies cannot be discarded. To go 
around this problem anoctamins’ double tagged constructs started already to be cloned 
and they will allow to normalize the protein expressed at the cell surface to the total 
amount that is being expressed eliminating the problem of plasmid uptake variance. 
On the other hand, Ano6 exhibit a more intracellular localization than Ano1 for all cell 
lines. Although it seems that Ano6 has a higher propensity to migrate to the cell surface 
in F508del-CFTR expressing cells that cannot be said for sure. It was observed that 
Ano6 transfected WT-CFTR cells had a bigger tendency to die than ΔF cells after 24 
hours of transfection. This is not unreasonable since that besides the recognised pro-
apoptotic role of CFTR[88], also Ano6 / ORCC are reported to be involved in the Fas-
ligand (FasL)-induced apoptotic cell death[24, 89] and by overexpressing Ano6 in WT-
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CFTR presence a synergistic process can be occurring enhancing cell death. Having this 
in mind, it’s possible that the cells expressing Ano6 preferentially localized at the cell 
surface are the ones that more easily die complicating the detection of Ano6 on this 
location. It would be interesting to assess the amount of cell death by a caspase 3 activity 
assay, when WT-CFTR and Ano6 are co-expressed and comparing it when Ano6 is co-
expressed with F508del-CFTR instead. 
 
 
5.3 Co-immunoprecipitation of CFTR with Ano1 and Ano6 
 
The co-immunoprecipitation assay revealed that Ano1 and WT-CFTR share a direct 
interaction but it seems that it’s not established through their PDZ binding domains since 
co-immunoprecipitation of both proteins was also observed when Ano1 PDZ binding 
domain was disrupted. The same does not occur with ΔF-CFTR because no co-
immunoprecipitation was detected with Ano1 eGFP. Comparing with the 
immunofluorescence results this is expected since Ano1 was mainly detected at the cell 
surface on both WT- (cell surface localized) and F508del-CFTR (intracellular localized) 
expressing cells. 
Still, when TMEM16A antibody was used instead of anti-GFP to detect Ano1 without 
the GFP tag a double band was detected on the input sample suggesting that two forms 
of Ano1 maturation are present, however if this was the case the same should have been 
seen with the anti-GFP Ab, which was not the case. More interestingly, the anti-
TMEM16A is able to detected a potential co-immunoprecipitation of Ano1 when ΔF-
CFTR is pulled-down, but this signal is at the same level as the upper band of the input 
while the one detected in the WT pull-down, using the same antibody, matches the size 
of the input lower band (near of Ano1 known size, ≈114 kDa). Even though this 
TMEM16A Ab is advertised as monoclonal it appears that it is recognising a protein other 
than Ano1. The epitope sequence recognized by the antibody has not been disclosed so 
there is no way to be sure if the antibody can be detecting for example another anoctamin 
(even though anoctamins sequence has not a high homology some similarity is present). 
Nonetheless it is possible to speculate that maybe TMEM16A Ab is binding to Ano8 since 
the band size is similar to the one expected to this protein (≈133 kDa) and being an 
intracellular protein[66] it cannot be discarded that co-immunoprecipitates with F508del-
CFTR. 
Ano6 eGFP showed similar results to Ano1 eGFP, co-immunoprecipitating with WT-
CFTR but not with ΔF. A double band was detected for Ano6 both in the input as in the 
WT-CFTR pull-down, suggesting the presence of a glycosylated and non-glycosylated 
form since Ano6 has six potential N-glycosylation sites. These results suggest that 
probably Ano6 is also express at the cell surface and interacts with CFTR, although we 
were unable to clearly detect it on that location maybe because of the previously 
proposed reasons. Another hypothesis is that a cross-talking phenomena between the 
endoplasmic reticulum and the PM may be occurring, similar to the one observed on 
yeast cells for Ist2 proteins which are related with the TMEM16 family on mammals[90, 91]. 
Ano6 and WT-CFTR do not interact through the PDZ binding domain because Ano6 has 
no predicted PDZ motif. 
 
 
5.4 CFTR influence on Ano1 and Ano6 function 
 
At any rate, the experiments demonstrate that expression of either Ano1 or Ano6 has 
large impact on whole cell conductances. The fact that Ano1 was spontaneously active 
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in BHK cells and that Ano6 expression in WT-CFTR expressing cells induced strong 
apoptosis made a functional analysis rather difficult. 
Therefor was not possible to infer about CFTR influence on Ano1 activation since both 
WT- and F508del-CFTR stably expressing cells that were transiently transfected with 
Ano1 demonstrated an extremely large conductance that didn’t allow to distinguish a 
possible effect of CFTR on further Ano1 activation since the measured values were 
already near the maximum detected by the set-up. This issue can possibly be circumvent 
by generating inducible Ano1 cell lines that stably express the tetracycline repressor 
protein, allowing for inducible expression of Ano1 gene upon the addition of doxycycline, 
enabling the regulation of gene expression level[92], therefor avoiding saturating levels 
and maybe reducing the overwhelming whole cell currents produced. 
On the other hand it was observed that Ano1 exerted an effect on CFTR activation, 
partially inhibiting WT-CFTR response to IBMX/FSK. This observation is probably due to 
the total whole cell currents which were so large that reached the limit of resolution of 
the patch clamp set-up. Although this Ano1 influence on CFTR activation should not be 
as pronounced as what it was seen, the results are actually in agreement with what was 
previously described in Ousingsawat and colleagues’ paper[16] where IBMX/FSK 
activated currents were reduced in HEK293 cells co-expressing CFTR and Ano1 when 
compared with cells only expressing CFTR. This interaction may suggest a mechanism 
of CFTR regulation to prevent an over-activation of the channel which could explain the 
higher Ano1 expression and cell surface localization when WT-CFTR is present instead 
of ΔF-CFTR, since the absence of the WT form would no longer require this regulatory 
function of Ano1. 
The functional assay for Ano1 mutant on the PDZ binding domain corroborates the 
results obtained by co-immunoprecipitation which suggested that CFTR and Ano1 do not 
physically interact through the PDZ domain, since CFTR response to IBMX/F stimulation 
is similar on cells co-expressing Ano1 and on cells co-expressing Ano1 L982A (PDZ 
binding domain mutant). 
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6 Future Perspectives 
 
The obtained results are not only a stimulus to continue the pursuit for the cross-talk 
between anoctamins and CFTR, looking deeper to their regulatory pathways trying to 
find common points that will allow to understand the mechanism underneath this 
relationship, but also allow the establishment of other experimental procedures which 
will help to clarify some of the results observed. 
One of the first observations that we want to confirm is the difference in Ano1, -6 and 
-9 gene expression apparently influenced by CFTR. In order to do that we propose to 
perform a real-time PCR to fully quantify the endogenous mRNA levels of the referred 
anoctamins, using as template the cDNA from parental CFBE and stably expressing WT- 
and F508del-CFTR. Following this, it would also be interesting to study if the disparity in 
anoctamins’ expression is reflected on the size of current produced. This could be 
accomplished by an Ussing chamber assay. 
After observing the differential expression of Ano1 on the cell surface of WT- and 
F508del-CFTR expressing cells it makes sense to follow up this study with a more 
elegant immunofluorescence assay, in order to reduce the problems related with the 
plasmid uptake variance which are characteristic of the over-expressing systems. We 
propose to assess Ano1 and Ano6 cell localization, using double tagged constructs 
which will allow to detect the total protein amount and the one localized only on the cell 
surface. The constructs were already created with the cloning of a FLAG tag into Ano1, 
-6 and -9 already fused with fluorescent proteins (for plasmid maps see appendices 
section). 
The major cell death witnessed when cells co-express WT-CFTR and Ano6 raises the 
question if these two proteins are involved in a synergistic pro-apoptotic mechanism. In 
order to better clarify this possible effect, cell apoptosis can be quantified by a caspase 
3 activity assay when co-expressing co-expressing either WT-CFTR / Ano6 or F508del-
CFTR / Ano6. 
The observation of direct interaction between CFTR and Ano1 and Ano6 lifts up the 
question of how are they communicating, through which domains is this interaction 
established? After discarding the PDZ binding domain hypothesis which other domains 
can be involved? 
It was not possible to accomplish all the proposed objectives in time for this thesis 
submission, namely the ones related with the functional assays. The effect of CFTR on 
Ano6 function still remains unclear as the effect on Ano1. Possibly a new system with 
inducible protein expression can be generated to avoid the major cell death and the large 
constitutive currents observed, respectively, which hampered the functional analysis. 
 
The understanding of CFTR and anoctamins interaction, regulation pathways and 
their cross-talk is very important since we may be in the presence of a potential 
alternative pharmacological target for CF disease. If this relationship between these two 
protein families is disclosed new drugs can be designed in order to enhance chloride 
secretion maybe by overstimulating anoctamins (because their expression / activity in 
the airways is much lower than CFTR’s) and restore this process which is impaired in 
CF. 
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8 Appendices  
 
8.1 Appendix I – pcDNA3.1 Ano1 eGFP plasmid map 
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FLAG-tag was cloned between positions 2128/2129, into Ano1’s first extracellular 
loop: 
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8.2 Appendix II – pcDNA3.1 Ano1 FLAG eYFP plasmid map 
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FLAG-tag was cloned between positions 2128/2129, into Ano1’s first extracellular 
loop: 
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8.3 Appendix III – pcDNA3.1 Ano1 FLAG CFP plasmid map 
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FLAG-tag was cloned between positions 2128/2129, into Ano1’s first extracellular 
loop: 
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8.4 Appendix IV – pIRES Ano1 eGFP CD8 plasmid map 
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8.5 Appendix V – pIRES Ano1 L982A CD8 plasmid map 
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8.6 Appendix VI - pcDNA3.1 Ano6 FLAG eGFP plasmid map 
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FLAG-tag was cloned between positions 2012/2013, into Ano6’s first extracellular 
loop: 
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8.7 Appendix VII – pIRES Ano6 eGFP CD8 plasmid map 
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8.8 Appendix VIII – pcDNA3.1 Ano9 FLAG eGFP plasmid map 
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FLAG-tag was cloned between positions 1638/1639, into Ano9’s first extracellular 
loop: 
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8.9 Appendix X – Live-cell imaging of Ano1 and Ano6 eGFP tagged 
 
a) Parental BHK cell line 
 
b) BHK WT-CFTR cell line 
 
c) BHK F508del-CFTR cell line 
 
Figure 8.1 – Immunocytochemistry (live imaging) of eGFP tagged Ano1 (green) when transiently 
overexpressed in non-stimulated a) parental BHK cells, b) BHK WT-CFTR (cells were firstly tripsinized and 
then seeded on Poly-L-Lysine cover slips) and c) BHK F508del-CFTR. Scale=10 µm. 
 
  
Ano1 (eGFP) Lipid marker Merge 
a) Parental BHK cells 
Ano1 (eGFP) Lipid marker Merge 
Ano6 (eGFP) Lipid marker Merge 
Ano1 (eGFP) Lipid marker Merge 
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Figure 8.2 – Immunocytochemistry (live imaging) of eGFP tagged Ano6 (green) when transiently 
overexpressed in non-stimulated a) parental BHK cells, b) BHK WT-CFTR (cells were firstly tripsinized and 
then seeded on Poly-L-Lysine cover slips) and c) BHK F508del-CFTR. Scale=10 µm. 
  
Ano6 (eGFP) Lipid marker Merge 
b) BHK WT-CFTR cells 
c) BHK F508del-CFTR cells 
Ano6 (eGFP) Lipid marker Merge 
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8.10 Appendix XI – Anoctamin constructs testing 
 
 
Figure 8.3 – Digestion of pcDNA3.1 Ano1 FLAG eGFP, YFP and CFP, Ano6 FLAG eGFP and Ano9 FLAG 
eGFP with Pst I and Ssp I. The expected fragments were obtained for all the plasmids. 
 
 
 
 
 
  
Total Ano1 (eGFP) Membrane Ano1 (FLAG) Merge 
a) 
Total Ano1 (YFP) Membrane Ano1 (FLAG) Merge 
b) 
Pst I Pst I Ssp I 
Ano1 FLAG 
3000 
500 
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Figure 8.4 – Immunocytochemistry of FLAG on HeLa Kyoto transiently transfected with a) Ano1 FLAG eGFP, 
b) Ano1 FLAG YFP, c) Ano9 FLAG eGFP and permeabilized with 0.1% Triton-X and d) Ano9 FLAG eGFP 
but not permeabilized. The FLAG staining worked well for all the plasmids except in Ano9 case for which 
cells needed to be permeabilized, however this was expected since Ano9 is known to be intracellular 
localized[66].Scale=100 µm 
 
 
 
 
 
Figure 8.5 – HEK293 cells were transfected with Ano6 FLAG eGFP and whole-cell currents were measured 
by patch clamp before and after stimulation with 1µM ionomycin, using a voltage ramp protocol (-100mV – 
100mV). a) Average whole-cell current density at 100 mV and b) current–voltage (I/V) relationships of resting 
currents and activated by 1 µM ionomycin in Ano6 FLAG eGFP-overexpressing and non-transfected HEK 
cells. Ano6 didn’t show any signal of activation when cells were stimulated with ionomycin, however when 
currents in transfected cells are compared with the ones in non-transfected it’s possible to see a bigger 
outwardly rectifying behaviour and resting cell current on the first ones. This suggests that although Ano6 is 
producing currents the FLAG insertion seems to have desensitized Ano6 for calcium activation. These tests 
are still in progress. Mean ± SEM, n = number of cells measured. 
 
b) a) 
Total Ano9 (eGFP) Ano9 (FLAG) Merge 
Total Ano9 (eGFP) Ano9 (FLAG) Merge 
c) 
d) 
